EP4099975A1 - Method for obtaining an aqueous extract of lavender, compositions comprising such an extract and their cosmetic uses - Google Patents
Method for obtaining an aqueous extract of lavender, compositions comprising such an extract and their cosmetic usesInfo
- Publication number
- EP4099975A1 EP4099975A1 EP21702221.9A EP21702221A EP4099975A1 EP 4099975 A1 EP4099975 A1 EP 4099975A1 EP 21702221 A EP21702221 A EP 21702221A EP 4099975 A1 EP4099975 A1 EP 4099975A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- extract
- skin
- lavender
- weight
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 108
- 235000010663 Lavandula angustifolia Nutrition 0.000 title claims abstract description 79
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 239000001102 lavandula vera Substances 0.000 title claims abstract description 65
- 235000018219 lavender Nutrition 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 39
- 239000002537 cosmetic Substances 0.000 title claims abstract description 33
- 239000006286 aqueous extract Substances 0.000 title claims abstract description 22
- 244000178870 Lavandula angustifolia Species 0.000 title claims abstract description 18
- 150000007524 organic acids Chemical class 0.000 claims abstract description 36
- 235000005985 organic acids Nutrition 0.000 claims abstract description 36
- 235000000346 sugar Nutrition 0.000 claims abstract description 35
- 150000008163 sugars Chemical class 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 150000002989 phenols Chemical class 0.000 claims abstract description 28
- 239000002773 nucleotide Substances 0.000 claims abstract description 26
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 26
- 108091032955 Bacterial small RNA Proteins 0.000 claims abstract description 24
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims abstract description 23
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims abstract description 22
- 229940068041 phytic acid Drugs 0.000 claims abstract description 22
- 235000002949 phytic acid Nutrition 0.000 claims abstract description 22
- 239000000467 phytic acid Substances 0.000 claims abstract description 22
- 230000004888 barrier function Effects 0.000 claims abstract description 12
- 230000008439 repair process Effects 0.000 claims abstract description 9
- 230000003647 oxidation Effects 0.000 claims abstract description 8
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 8
- 230000003711 photoprotective effect Effects 0.000 claims abstract description 6
- 230000007321 biological mechanism Effects 0.000 claims abstract description 5
- 241000196324 Embryophyta Species 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 210000004761 scalp Anatomy 0.000 claims description 8
- 230000009759 skin aging Effects 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 230000037067 skin hydration Effects 0.000 claims description 7
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 235000013824 polyphenols Nutrition 0.000 claims description 5
- 239000000287 crude extract Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 3
- 206010001488 Aggression Diseases 0.000 abstract description 7
- 230000016571 aggressive behavior Effects 0.000 abstract description 7
- 230000001965 increasing effect Effects 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 3
- 230000036571 hydration Effects 0.000 abstract description 3
- 238000006703 hydration reaction Methods 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 63
- 244000165082 Lavanda vera Species 0.000 description 59
- 229940093915 gynecological organic acid Drugs 0.000 description 32
- 229940083980 lavender extract Drugs 0.000 description 32
- 235000020723 lavender extract Nutrition 0.000 description 32
- 229960003987 melatonin Drugs 0.000 description 28
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 27
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 27
- 239000012071 phase Substances 0.000 description 23
- 238000000605 extraction Methods 0.000 description 22
- 229920002477 rna polymer Polymers 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 16
- 102000053602 DNA Human genes 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 239000000341 volatile oil Substances 0.000 description 15
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 102100030547 Serotonin N-acetyltransferase Human genes 0.000 description 12
- 238000007390 skin biopsy Methods 0.000 description 11
- 210000003780 hair follicle Anatomy 0.000 description 10
- 239000003642 reactive oxygen metabolite Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000035882 stress Effects 0.000 description 9
- 244000041506 Lavandula officinalis Species 0.000 description 8
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 210000002752 melanocyte Anatomy 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000005778 DNA damage Effects 0.000 description 5
- 231100000277 DNA damage Toxicity 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108091093078 Pyrimidine dimer Proteins 0.000 description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- -1 terpene compounds Chemical class 0.000 description 5
- 235000007586 terpenes Nutrition 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000011090 malic acid Nutrition 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000013635 pyrimidine dimer Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- 150000003505 terpenes Chemical class 0.000 description 4
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000033316 Acquired hemophilia A Diseases 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 206010064127 Solar lentigo Diseases 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- ASJWEHCPLGMOJE-LJMGSBPFSA-N ac1l3rvh Chemical class N1C(=O)NC(=O)[C@@]2(C)[C@@]3(C)C(=O)NC(=O)N[C@H]3[C@H]21 ASJWEHCPLGMOJE-LJMGSBPFSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- UPUOLJWYFICKJI-UHFFFAOYSA-N cyclobutane;pyrimidine Chemical class C1CCC1.C1=CN=CN=C1 UPUOLJWYFICKJI-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000769 gas chromatography-flame ionisation detection Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000036564 melanin content Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Polymers 0.000 description 3
- 150000007965 phenolic acids Chemical class 0.000 description 3
- 235000009048 phenolic acids Nutrition 0.000 description 3
- 210000004560 pineal gland Anatomy 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 239000012855 volatile organic compound Substances 0.000 description 3
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 108030000666 Aralkylamine N-acetyltransferases Proteins 0.000 description 2
- 108010074515 Arylalkylamine N-Acetyltransferase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 240000002791 Brassica napus Species 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 239000004287 Dehydroacetic acid Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 235000002997 Lavandula Nutrition 0.000 description 2
- 235000004431 Linum usitatissimum Nutrition 0.000 description 2
- 240000006240 Linum usitatissimum Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MVAWJSIDNICKHF-UHFFFAOYSA-N N-acetylserotonin Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CNC2=C1 MVAWJSIDNICKHF-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000001053 badasse Nutrition 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 239000008407 cosmetic solvent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 229940061632 dehydroacetic acid Drugs 0.000 description 2
- 235000019258 dehydroacetic acid Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 239000008131 herbal destillate Substances 0.000 description 2
- 239000010903 husk Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 244000056931 lavandin Species 0.000 description 2
- 235000009606 lavandin Nutrition 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 2
- UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical compound CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- HAAYBYDROVFKPU-UHFFFAOYSA-N silver;azane;nitrate Chemical compound N.N.[Ag+].[O-][N+]([O-])=O HAAYBYDROVFKPU-UHFFFAOYSA-N 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 1
- XOMRRQXKHMYMOC-NRFANRHFSA-N (3s)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-NRFANRHFSA-N 0.000 description 1
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 description 1
- SABOFQQPIQQDHH-UHFFFAOYSA-N 3-[2-(2-fluorophenyl)pyrazol-3-yl]-1-[3-(trifluoromethyl)phenyl]pyridazin-4-one Chemical compound FC1=CC=CC=C1N1C(C=2C(C=CN(N=2)C=2C=C(C=CC=2)C(F)(F)F)=O)=CC=N1 SABOFQQPIQQDHH-UHFFFAOYSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 241000001503 Anogeissus Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000238582 Artemia Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 235000005903 Dioscorea Nutrition 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 235000003368 Ilex paraguariensis Nutrition 0.000 description 1
- 244000188472 Ilex paraguariensis Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-OZRXBMAMSA-N N-acetyl-beta-D-mannosamine Chemical compound CC(=O)N[C@@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-OZRXBMAMSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- KVTFEOAKFFQCCX-UHFFFAOYSA-N N-hexadecanoylglycine Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(O)=O KVTFEOAKFFQCCX-UHFFFAOYSA-N 0.000 description 1
- 108010066427 N-valyltryptophan Proteins 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- MXKNVYNTUDZGFO-DWMULOEHSA-N O[C@H]1CN[C@H](C(O)=O)C1.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O Chemical compound O[C@H]1CN[C@H](C(O)=O)C1.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O MXKNVYNTUDZGFO-DWMULOEHSA-N 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OLGWXCQXRSSQPO-MHARETSRSA-N P(1),P(4)-bis(5'-guanosyl) tetraphosphate Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=C(NC2=O)N)=C2N=C1 OLGWXCQXRSSQPO-MHARETSRSA-N 0.000 description 1
- 241000206754 Palmaria palmata Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000011925 Passiflora alata Nutrition 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 235000011922 Passiflora incarnata Nutrition 0.000 description 1
- 240000002690 Passiflora mixta Species 0.000 description 1
- 235000013750 Passiflora mixta Nutrition 0.000 description 1
- 235000013731 Passiflora van volxemii Nutrition 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 235000010674 Prunella vulgaris Nutrition 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 239000004133 Sodium thiosulphate Substances 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SFRPDSKECHTFQA-ONOWFSFQSA-N [(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] propanoate Chemical compound CCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SFRPDSKECHTFQA-ONOWFSFQSA-N 0.000 description 1
- VEWKDTRPCDYKTR-QLMRWRAFSA-N [(2s)-2-[(2r)-3,4-di(hexadecanoyloxy)-5-oxo-2h-furan-2-yl]-2-hexadecanoyloxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@H]1OC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=C1OC(=O)CCCCCCCCCCCCCCC VEWKDTRPCDYKTR-QLMRWRAFSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000004790 biotic stress Effects 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229940075639 palmitoyl glycine Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020733 paullinia cupana extract Nutrition 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 244000022778 quail grass Species 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000007845 reactive nitrogen species Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 150000004819 silanols Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001331 thermoregulatory effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
Definitions
- the invention relates to the field of cosmetics and more particularly to active ingredients of natural origin used in the preparation of cosmetic formulation for improving the appearance of the skin or protecting it.
- the invention relates to a process for obtaining an aqueous extract of lavender as well as the extract enriched in small RNA, in sugars, in phenolic compounds, in organic acids obtained by the process, the cosmetic compositions comprising such extracts and their cosmetic uses for the care of the skin, scalp and integuments and more particularly to protect the skin from external aggressions and oxidation, fight against the signs of skin aging, increase photoprotection, lighten the skin, improve skin hydration, strengthen the barrier function, soothe the skin or to improve the biological mechanisms associated with skin repair at night.
- Plants of the genus Lavandula commonly known as lavender, form a group of 47 species.
- Lavandula angustifolia also called true lavender
- lavandin a hybrid resulting from the crossing of true lavender and lavender aspic.
- Essential oil is generally obtained by hydrodistillation. The previously dried flowers are subjected to a stream of water vapor which entrains the volatile or soluble constituents are then recondensed to obtain a hydrosol (or floral water) and a supernatant comprising the lipid parts of the plant and constituting the essential oil.
- Lavender EOs are very fragrant and predominantly include volatile monoterpenes such as linalool and linalyl acetate. In true lavender I ⁇ E, both are present at about 30%. Lavender EO is particularly recognized for its sedative, analgesic, analgesic, anti-inflammatory, antiseptic and antibacterial properties. It is also antispasmodic and decongestant and indicated to soothe skin conditions and promote healing. Lavender EO is also indicated to improve sleep disorders and various tensions (anxiety, stress, etc.).
- Lavender floral waters contain less than a few percent of essential oil-like volatile organic compounds, as well as the water-soluble compounds of the plant. Floral water has the same properties as lavender essential oil, but more attenuated due to the lower concentrations of terpene compounds.
- the extract obtained is rich in polyphenols and flavonoids, but does not contain other compounds of interest such as amino acids, organic acids or proteins.
- phenolic acids are not extracted by this type of technique, in fact these molecules are mainly extracted in a polar solvent and ideally with water.
- One problem which the invention proposes to solve is to provide a new aqueous extract of lavender meeting the requirements of the current cosmetic market concerning the criteria of naturalness and nevertheless exhibiting remarkable biological efficacy.
- Another problem which the invention proposes to solve is to provide a new aqueous extract of lavender which does not represent the defects of the extracts currently known, namely a strong odor, an instability of the EOs in the formulas for topical application, or else an irritant or allergenic nature due to the presence of terpene molecules such as linalool.
- a problem which the invention still proposes to solve is to provide a new aqueous extract of lavender enriched with compounds known for their effectiveness on the skin such as small RNAs, sugars, phenolic compounds and organic acids.
- the inventors have developed a new extract of lavender flower specifically enriched with small RNAs, sugars, phenolic compounds and organic acids, and which does not have the drawbacks of the methods of the prior art cited, such as, for example, use of potentially toxic detergents and solvents in cosmetics.
- the extract thus obtained can be used in cosmetics for the care of the skin, scalp and integuments and more particularly to protect the skin from external aggressions and oxidation, to fight against the signs of skin aging, increase photoprotection, lighten the skin, improve skin hydration, strengthen the barrier function or even soothe the skin.
- the first subject of the invention is a process for obtaining an aqueous extract of aerial parts of lavender, comprising the following steps: a) the aerial parts of lavender are brought into contact with water; b) phytic acid is added at a concentration of between 1 and 10 mM in the mixture obtained in a) at a pH of between 10 and 11; c) the pH of the mixture obtained in b) is then adjusted to a value between 6 and 8; d) the mixture obtained in c) is purified so as to eliminate the residual solid plant material and to obtain a purified aqueous crude extract; and e) the pH is checked and it is readjusted if necessary to a value between 6 and 8, preferably between 6 and 6.5.
- a second subject of the invention is an aqueous extract of aerial parts of lavender enriched in small RNA with a length of at most 150 nucleotides, in sugars, in phenolic compounds and in organic acids, devoid of DNA, obtainable by the process of one of claims 1 to 5, characterized in that it comprises, by weight of the total weight of the extract, 10 to 30 g / kg of dry weight, containing 2 to 10 g / kg of sugars, 100 to 1500 mg / kg of organic acids, 500 to 2000 mg / kg of phenolic compounds and 40 to 200 mg / kg of low molecular weight RNA up to a length of 150 nucleotides.
- the third object of the invention is a cosmetic composition comprising, as an active ingredient, an effective amount of the extract of one of claims 6 or 7, and a physiologically acceptable medium.
- a fourth subject of the invention is the cosmetic use of the composition of the invention, for the care of the skin, the scalp and integuments, more particularly for protecting the skin from external attacks and from oxidation. , fight against the signs of skin aging, increase photoprotection, lighten the skin, improve skin hydration, strengthen the barrier function, soothe the skin, or even to improve the biological mechanisms associated with the repair of the skin during night.
- FIG. 2 Analysis of RNAs of small molecular weight by the Bioanalyzer 2100.
- A lavender extract obtained according to the process of the invention
- B conventional lavender extract.
- lavender is meant all species of the genus Lavandula, as well as their hybrids (such as lavandin).
- tissue parts are meant the stems and flowers of lavender. The seeds are included in the “aerial parts” within the meaning of the invention.
- small RNA or "RNA of small molecular weight”, or "small RNA of a maximum length of 150 nucleotides” is meant non-coding RNAs (ribonucleic acids), of low molecular weight, of a length of at most 150 nucleotides, such as all types of small non-messenger RNAs, single and / or double strands, for example microRNAs, interfering RNAs, introns, small nuclear RNAs or even any fragment of RNA. Electrophoresis analysis shows that the small RNAs present in the lavender extract of the invention have varied molecular weights of approximately between 30 and 150 nucleotides.
- organic acids is meant ⁇ -hydroxy acids (or AHAs), that is to say carboxylic acids derived from fruit or plant sugars, such as glycolic, malic, citric or tartaric acids. , succinic and uronic.
- phenolic compounds or polyphenols
- molecules of plant origin which have an aromatic ring carrying one or more hydroxyl groups, such as phenolic acids, flavonoids or their derivatives.
- Polyphenolic compounds are known to be powerful antioxidant molecules.
- sucrose means monosaccharides and more particularly glucose and fructose as well as oligo and polysaccharides.
- RNAs of interest means all of the molecules present in the lavender extract of the invention and in particular, small RNAs with a length of at most 150 nucleotides, sugars, phenolic compounds and organic acids.
- compositions described in the present application can be any compositions described in the present application.
- compositions or component may include additional ingredients, but only if the additional ingredients do not modify the basic characteristics or the new characteristics of the composition or the use described herein. request.
- a "physiologically acceptable medium” means a vehicle suitable for contact with the outer layers of the skin or mucous membranes, without toxicity, irritation, undue allergic and similar response or intolerance reaction, and proportionate to a ratio. reasonable benefit / risk.
- topical application is meant the fact of applying or spreading the aqueous extract enriched in small RNA with a length of at most 150 nucleotides, in sugars, in phenolic compounds and in organic acids according to invention, or a composition containing it, on the surface of the skin or of a mucous membrane.
- Skin refers to the skin of the face, including the area around the eyes and mouth, nose, forehead, neck, hands, but also the skin of the whole body.
- Scalp refers to the skin covering the skull, including hair follicles and inter-follicular skin spaces.
- the term “reinforcing the barrier function” means that the protective properties of the skin against external aggressions (UV radiation, visible or infrared light, pollution, microorganisms, etc.) are improved.
- Lightening the skin means reducing the intensity of the color of the skin linked to the melanin content of the epidermis, either homogeneously or locally by acting on pigment disorders, such as dark spots. senescence or senile lentigo.
- an effective amount is meant the minimum amount of extract according to the invention which is necessary to obtain at least one of the desired biological activities, in particular to exhibit an antioxidant activity vis-à-vis the reactive species of l. oxygen, increase melatonin or decrease melanin, or any other biological marker studied, without this quantity being toxic.
- skin hydration is meant the water content and distribution of the upper layers of the epidermis.
- “Improvement of skin hydration” means any improvement in changes in the external appearance of the skin due to dehydration such as, for example, dryness, tightness and discomfort, whether this condition is related to internal or external factors, such as adverse environmental conditions.
- signals of skin aging is meant any changes in the external appearance of the skin due to aging such as, for example, fine lines and wrinkles, cracks, bags under the eyes, dark circles, wilting, loss of elasticity, firmness and / or tone of the skin, but also any internal skin changes that do not systematically result in a modified external appearance such as, for example, thinning of the skin, or all internal degradation of the skin resulting from environmental stresses such as pollution and solar radiation including UV rays.
- signals of skin aging also means pigmentary disorders such as senile lentigo or solar lentigo.
- exital attacks we mean solar radiation, including visible light, UV and infrared radiation, pollution, which may come from the ambient atmosphere outside or inside homes and including particles of different sizes (10 ⁇ m for PM 10, 2.5 ⁇ m for PM 2.5, or less than 100 nm for ultrafine particles) as well as several chemical elements (volatile organic compounds, polycyclic aromatic hydrocarbons, heavy metals. .).
- RNA extraction protocols use solvents unsuitable for cosmetic use (Zumbo, P. 2014 "Phenol-chloroform Extraction", 2014). These methods aim to obtain nucleic acids (RNA or DNA or small RNA) completely purified, that is to say free of any other molecule of interest such as secondary metabolites, vitamins, sugars, peptides, etc. which may have beneficial effects for the skin and are therefore of cosmetic interest.
- Document FR2831168 is also known, which describes a process for obtaining a plant extract rich in nucleic acids (DNA and / or RNA).
- the process uses cellulolytic enzymes.
- Patent documents EP1723958 and W003101376 are also known from the prior art which describe a composition for topical application comprising a synthetic double-stranded RNA oligonucleotide with a length of 12 to 40 nucleotides, of known sequence having a siRNA function ("short interfering").
- Document FR 1502361 (also published under the number WO2017084958) is also known, which describes a process for obtaining an aqueous extract of plants, enriched with low molecular weight ribonucleic acids (RNA), to prepare cosmetic compositions. .
- the process uses EDTA at a concentration of between 2 and 15 mM.
- phytic acid is a naturally occurring molecule found in the husk of seeds, such as grains and legumes. Therefore, the use of phytic acid makes it possible to obtain a lavender extract that is 100% of natural origin while maintaining good extraction efficiency of the phytomolecules contained in the plant. The efficiency of extracting small RNAs as well as those of other compounds present in lavender flowers such as sugars, phenolic compounds, or organic acids such as tartaric, malic or citric acid.
- the first subject of the invention is thus an extraction process used to obtain an aqueous extract of the aerial, dried or fresh parts of lavender.
- the extraction process of the invention makes it possible to obtain an extract rich in phytomolecules of cosmetic interest such as small RNAs with a maximum length of 150 nucleotides, sugars, phenolic compounds and acids. organic, avoiding the use of solvents that are not considered cosmetic solvents.
- a) of the process according to the invention the aerial parts of lavender are mixed with water.
- the water used is distilled, demineralized water or water rich in mineral salts and / or trace elements.
- the water preferably used is distilled water.
- the aerial parts of lavender are the lavender flowers and the small stems bearing the flowers.
- the species of lavender used is Lavandula angustifolia or true lavender.
- the aerial parts of lavender are in dry form.
- the aerial parts of lavender are ground into powder form before being placed in the presence of water in step a). Grinding the aerial parts of lavender is a mechanical action that allows better extraction. Mechanical grinding to obtain the plant material in powder form, followed by alkaline lysis in the presence of phytic acid promotes the complete destructuring of cell membranes and in particular of the nuclear membrane.
- the aerial parts of lavender previously ground in powder form are mixed with water, in step a) in a plant material / water ratio of 3 to 20% by weight / weight, more preferably in a ratio between 3 and 10%, for example in a ratio of 3%, 5% or 10% (weight / weight).
- Phytic acid is then added in step b) to the mixture obtained in a).
- the pH at this stage should be basic, at a value between 10 and 11 and must therefore be adjusted, if necessary, by adding sodium hydroxide (NaOH).
- NaOH sodium hydroxide
- the pH is basic, between 10 and 11.
- the pH is adjusted to a value between 10.5 and 11. Indeed, this pH level, associated with the action of phytic acid, causes the destructuring of the cell membrane, including the nuclear membrane, the lysis of cells and the denaturation of DNA (the 2 strands of the double helix are separated).
- Phytic acid weakens and destructures the pecto-cellulosic membranes of plant cells by sequestering by complexation the divalent ions such as calcium ions which form ionic bridges between the pectin molecules surrounding the cellulose microfibrils. The consequence of this is to promote the release of the cellular content during the extraction.
- the step of treatment with phytic acid is essential for enriching the extract in RNA of small molecular weights and more generally ensuring a better yield of extraction of the other phytomolecules of interest; namely sugars, phenolic compounds and organic acids.
- the extraction process makes it possible to enrich the final extract with low molecular weight RNA through the use of an aqueous extraction solution containing in particular a natural chelating agent such as phytic acid.
- Phytic acid is a molecule found naturally in the husk of seeds, such as grains and legumes. Phytic acid is present in the form of calcium salts or sometimes magnesium, and it plays an important role for the plant, for example, it is the main source of phosphorus.
- the phytic acid used is a phytic acid powder in the form of sodium salt at a concentration preferably between 1 and 10 mM, preferably between 1 and 5 mM and more preferably the concentration is 3. mM.
- the invention works particularly well for a phytic acid concentration between 2 and 3 as described in Table 1 below. It is thus observed that for only 2.25 mM of phytic acid the same results are obtained as with EDTA at 10 mM in terms of concentration of small RNA, as well as a similar overall extraction yield.
- a concentration of 3 mM allows an optimum extraction yield of RNAs of small molecular weights.
- the concentration of 3 mM is also optimal for having a better yield of other compounds of interest such as sugars, phenolic compounds and organic acids. With a phytic acid concentration of 4.5 mM the extraction yield of RNAs of small molecular weight is even higher, but the overall extraction yield decreases.
- Stage b) of treatment with phytic acid preferably lasts at least 1 hour, at a temperature between 20 and 80 ° C. During this step, the mixture obtained in a) is advantageously stirred.
- step b) it is possible at the end of step b) to add diatomaceous earth in order to subsequently facilitate the separation between the solid residual plant material and the extract (soluble fraction) in step next.
- step c) the pH of the mixture obtained in b) is then adjusted to a value between 6 and 8.
- the pH can be adjusted by adding a solution of hydrochloric acid (HCl) or any other equivalent acid, compatible with cosmetic use. Acidification causes the sudden renaturation of DNA (re-pairing of the double helix strands). However, the chromosomal DNA, which is very long, does not not to re-pair completely and form insoluble tangles. On the contrary, the small RNAs remain in solution. DNA and small RNAs are thus separated into two distinct phases; a solid phase containing, among other things, chromosomal DNA, and a liquid phase containing, among other things, small RNAs.
- the pH adjustment step in step d) of the process according to the invention is an essential step for the optimum extraction of low molecular weight RNAs, as well as other phytomolecules of interest; namely sugars, phenolic compounds and organic acids.
- step d) the mixture obtained in c) is purified so as to remove the aerial parts of residual solid lavender and to recover the soluble part which constitutes the crude aqueous extract according to the invention.
- the mixture obtained in c) can be filtered through filters with a porosity greater than 30 ⁇ m so as to collect the filtrate.
- the mixture obtained in c) is centrifuged at low speed, for example for at least 10 min at 4000 g, so as to sediment the residual plant material in the pellet and recover the crude aqueous extract in the supernatant.
- a step e) the pH is checked and it is readjusted to a value between 6 and 8.
- the pH is readjusted to a value between 6 and 6.5, even more preferably to a value of 6, 5.
- the pH is readjusted by adding a solution of hydrochloric acid (HCl) or any equivalent acid compatible with cosmetic use.
- HCl hydrochloric acid
- step e) of the process according to the invention is an essential step in order to have optimum stability of the low molecular weight RNAs in the extract.
- the readjustment of the pH of step e) is preceded by at least one filtration of the crude aqueous extract obtained in d).
- Successive filtrations will be carried out by lowering the filtration threshold from 20 to 50 mih until a sterilizing filtration of 0.1 - 0.3 mih.
- the extract obtained in step e) can then be diluted in a physiologically acceptable solvent for cosmetic use, so that the dry weight is between 4 and 20 g / kg of dry extract relative to total weight of the diluted extract. This step improves the stability of the extract over time.
- the second subject of the invention is an aqueous extract of aerial parts of lavender enriched with small RNAs of a maximum length of 150 nucleotides, in sugars, in phenolic compounds, in organic acids and devoid of DNA, capable of to be obtained by the process described above.
- This extract does not contain DNA (deoxyribonucleic acid).
- a subject of the invention is also an aqueous extract of aerial parts of lavender enriched with small RNAs of a maximum length of 150 nucleotides, in sugars, in phenolic compounds and in organic acids, directly obtained by the method described. above.
- This extract does not contain DNA (deoxyribonucleic acid).
- an aqueous concentrated crude extract of amber to dark amber lavender having a dry weight of 10 to 30 g / kg, containing 2 to 10 g / kg of sugars, 100 to 1500 mg / kg of organic acids, 500 to 2000 mg / kg of phenolic compounds and 40 to 200 mg / kg of low molecular weight RNA with a maximum length of 150 nucleotides .
- the extracts obtained can exhibit significant variability depending on factors such as the place or year of harvest, the season, the climatic conditions, biotic stress, etc.
- the extract thus obtained can then be diluted in a physiologically acceptable solvent for cosmetic use, so that the concentration of the extract is then adjusted to a dry weight of between 4 and 20 g / kg of extract. dry relative to the total weight of the diluted extract.
- physiologically acceptable solvents examples include water, glycerol, ethanol, propanediol as well as its natural version called Zemea® from corn, butylene glycol, dipropylene glycol, ethoxylated or propoxylated diglycols, cyclic polyols or any mixture of these solvents.
- the extract obtained can be diluted to obtain a final concentration of 50% of butylene glycol derived from plants, or 50% of propanediol derived from plants or even 30% of glycerin derived from plants.
- the extract obtained by the process according to the invention is diluted in butylene glycol so that the diluted extract comprises a final butylene glycol concentration of 50%.
- This so-called diluted extract comprises by weight of the total weight of the extract from 4 to 20 g / kg of dry extract, 0.5 to 10 g / kg of sugars, 50 to 700 mg / kg of organic acids , 50 to 1500 mg / kg of phenolic compounds and 10 to 100 mg / kg of low molecular weight RNA with a maximum length of 150 nucleotides.
- a diluted extract of Lavandula angustifolia more particularly containing sugars at a concentration of 1.7 g / kg, organic acids at a content of 570 mg / kg, 620 mg. / kg of phenolic compounds and 45 mg / kg of low molecular weight RNA with a maximum length of 150 nucleotides.
- floral water and lavender essential oil mainly contain odorous molecules of terpene nature and do not contain RNA of small molecular weights of a maximum length of 150 nucleotides, nor of sugars. , nor of phenolic compounds or organic acids.
- the extract of the invention thus comprises a wide range of phytomolecules which may have beneficial effects on the skin, without presenting a risk of skin irritation or other damage to health.
- the lavender extract of the invention more particularly contains mono- and polysaccharides, which are present neither in floral water nor in essential oil of lavender.
- True lavender is part of the Lamiaceae family which has a particular metabolism known as CAM for Crassulacean Acid Metabolism.
- the plant stores organic acids and more particularly malic acid, citric acid and tartaric acid inside its cells.
- the process described in the invention makes it possible to extract these organic acids or AHAs. Applied to the skin, these AHAs reduce cell cohesion between the corneocytes, cause the desquamation of the horny layers and thus stimulate cell renewal.
- the lavender extract according to the invention is also enriched in phenolic compounds, such as phenolic acids. These water-soluble molecules known for their antioxidant activity contribute to the antioxidant and protective potential of the lavender extract of the invention.
- a third aspect of the invention is a cosmetic composition
- a cosmetic composition comprising an effective amount of an aqueous extract enriched in small RNA with a length of at most 150 nucleotides, in sugars, in phenolic compounds and in organic acids obtained according to the invention, as an active ingredient, and a physiologically acceptable medium.
- the aqueous extract enriched in small RNA with a length of at most 150 nucleotides, in sugars, in phenolic compounds and in organic acids, obtained according to the invention is advantageously used for the preparation of cosmetic compositions, as an ingredient. active.
- the extract of aerial parts of lavender according to the invention is added to the composition at a concentration of 0.05 to 5% by weight relative to the total weight of the composition, preferably at a concentration of 0, 1 to 2.5% by weight relative to the total weight of the composition and even more preferably at a concentration of 0.1 to 1.0% by weight relative to the total weight of the composition.
- composition which can be used according to the invention may be applied by any suitable route, in particular oral, or external topical, and the formulation of the compositions will be adapted by those skilled in the art.
- compositions according to the invention are provided in a form suitable for topical application.
- These compositions must therefore contain a physiologically acceptable medium, that is to say compatible with the skin and integuments, without risk of discomfort during their application and cover all suitable cosmetic forms.
- compositions for implementing the invention may in particular be in the form of an aqueous, hydroalcoholic or oily solution, an oil-in-water, water-in-oil or multiple emulsions; they can also be in the form of suspensions, or even powders, suitable for application to the skin, mucous membranes, lips and / or hair.
- compositions can be more or less fluid and also have the appearance of a cream, a lotion, a milk, a serum, an ointment, a gel, a paste or mousse. They can also be in solid form, such as a stick or be applied to the skin in the form of an aerosol.
- adjuvants necessary for the formulation such as solvents, thickeners, diluents, antioxidants, dyes, sunscreens, agents. self-tanning agents, pigments, fillers, preservatives, perfumes, odor absorbers, essential oils, vitamins, essential fatty acids, surfactants, film-forming polymers, etc.
- these adjuvants as well as their proportions are chosen so as not to harm the desired advantageous properties of the composition according to the invention.
- These adjuvants can, for example, correspond to 0.01 to 20% of the total weight of the composition.
- the fatty phase can represent from 5 to 80% by weight and preferably from 5 to 50% by weight relative to the total weight of the composition.
- the emulsifiers and co-emulsifiers used in the composition are chosen from those conventionally used in the field under consideration. For example, they can be used in a proportion ranging from 0.3 to 30% by weight relative to the total weight of the composition.
- the aqueous lavender extract of the invention can be encapsulated or included in a cosmetic vector such as liposomes or any other nanocapsule or microcapsule used in the field of cosmetics or adsorbed on powdery organic polymers, mineral supports such as talcs and bentonites.
- a cosmetic vector such as liposomes or any other nanocapsule or microcapsule used in the field of cosmetics or adsorbed on powdery organic polymers, mineral supports such as talcs and bentonites.
- composition according to the invention can comprise, in addition to the active ingredient according to the invention, at least one other active agent exhibiting cosmetic effects similar and / or complementary to those of the invention.
- the additional active agent (s) can be chosen from: anti-aging, firming, brightening, moisturizing, draining agents, promoting microcirculation, exfoliating, desquamating, stimulating the extracellular matrix, activating energy metabolism, antibacterial agents , antifungal, soothing, anti-radical, anti-UV, anti-acne, anti-inflammatory, anesthetics, providing a feeling of heat, providing a feeling of freshness, slimming.
- Such additional active agents can be chosen from the groups comprising:
- retinol retinol propionate, retinol palmitate
- vitamin B3 and more particularly niacinamide, tocopherol nicotinate;
- vitamin B5 vitamin B6, vitamin B12, panthenol
- vitamin C in particular ascorbic acid, ascorbyl glucoside, ascorbyl tetrapalmitate, magnesium and sodium ascorbyl phosphate;
- Amino acids such as arginine, ornithine, hydroxyproline, hydroxyproline dipalmitate, palmitoylglycine, hydroxylysine, methionine and its derivatives, N-acylated amino acid compounds;
- - natural or synthetic peptides including di-, tri-, tetra-, penta- and hexapeptides and their lipophilic derivatives, isomers and complexed with others species such as a metal ion (eg copper, zinc, manganese, magnesium, and the like).
- a metal ion eg copper, zinc, manganese, magnesium, and the like.
- peptides commercially known under the names of MATRIXYL®, ARGIRELINE®, CHRONOGEN TM, LAMINIXYL IS TM, PEPTIDE Q10 TM, COLLAXYL TM (patent FR2827170, ASHLAND®), PEPTIDE VINCI 01 TM (patent FR2837098, ASHLAND®), PEPTIDE VINCI 02 TM (patent FR2841781, ASHLAND®), ATPeptide TM (patent FR2846883, ASHLAND®) or the synthetic peptide of sequence Arg-Gly-Ser-NH2, marketed under the name ATPeptide TM by ASHLAND®;
- extracts of flax such as extracts of flax (Lipigegine TM, patent FR2956818, ASHLAND®), extracts of soybean, spelled, vine, rapeseed, flax, rice, corn, peas;
- Dynagen TM (patent FR2951946, ASHLAND®) or Actopontine TM (patent FR2944526, ASHLAND®);
- DHA - dehydroacetic acid
- lipids such as ceramides or phospholipids, oils of animal origin, such as squalene or squalane; vegetable oils, such as sweet almond, copra, castor, jojoba, olive, rapeseed, peanut, sunflower, wheat germ, corn germ, soybean oil, cotton, alfalfa, poppy, pumpkin, evening primrose, millet, barley, rye, safflower, passionflower, hazelnut, palm, apricot kernel, avocado, calendula ; ethoxylated vegetable oils, shea butter;
- - cyclic AMP and its derivatives activators of the adenylate enzyme cyclase and inhibitors of the enzyme phosphodiesterase, extract of Centella asiatica, asiaticoside and asiatic acid, methyl xanthines, theine, caffeine and its derivatives, theophylline, theobromine, forskolin, l esculin and esculoside, ACE inhibitors, Val-Trp peptide, neuropeptide Y inhibitor, enkephalin, Ginkgo biloba extract, dioscorea extract, rutin, extract of yerba mate, guarana extract, oligosaccharides, polysaccharides, carnitine, ivy extract, wrack extract, hydrolyzed extract of Prunella vulgaris, hydrolyzed extract of Celosia cristata, extract 6 'Anogeissus leiocarpus, extract of leaves of Manihot utilissima, palmitoylcarni
- a fourth subject of the invention is the cosmetic use of a composition comprising the lavender extract of the invention for caring for the skin, scalp and integuments, more particularly for protecting the skin from attacks. externalities and oxidation, fight against the signs of skin aging, increase photoprotection, lighten the skin, improve skin hydration, strengthen the barrier function, soothe the skin, or to improve the biological mechanisms associated with overnight skin repair.
- the skin is an organ composed of several layers (dermis, epidermis and stratum corneum), which covers the entire surface of the body and provides protective functions against external, sensitive, immune, metabolic, thermoregulatory or still barrier limiting dehydration.
- stratum corneum acts as a protective physical barrier, commonly known as the “skin barrier function”. This function is of major importance in tissue homeostasis and in protection from the external environment.
- the appearance of the skin can be modified by internal alterations (intrinsic aging, diseases and hormonal changes such as pregnancy) or external (environmental factors, such as pollution, sunlight, pathogens, variations temperature, etc.). All of these alterations affect not only the skin, but also the keratinous appendages such as body hair, eyelashes, eyebrows, nails and hair.
- the extract of the aerial parts of lavender of the invention has been tested on the main biomarkers associated with the mechanisms of repair of the skin during the night. Mechanisms that take place in the skin overnight include increased DNA repair, rate of cell proliferation, skin temperature, skin blood flow, incidence of itching, as well as permeability. of the skin barrier, leading to a loss of hydration (Matsui MS et al, Biological rhythms in the skin, Int. J. Mol. Soi. 2016, 17,801).
- the extract of aerial parts of lavender of the invention was in particular evaluated on the repair rate of pyrimidine dimers (CPD for Cyclobutane Pyrimidine Dimers).
- the day / night rhythm perceived at the level of the central nervous system includes the production of melatonin by the pineal gland (Slominski A.T. et al, Melatonin: A cutaneous perspective on its production, metabolism, and functions. J Invest Dermatol, 2018 March;
- Melatonin is also produced locally in the skin from tryptophan. These functions help to reduce the level of reactive oxygen and nitrogen species (ROS and RNS, for reactive oxygen species and reactive nitrogen species, respectively). In fact, in addition to its direct role as a free radical scavenger, melatonin stimulates the production of antioxidant enzymes such as catalase and superoxide dismutase and is involved in DNA repair. By optimizing the functioning of the mitochondria, melatonin also helps to increase the level of ATP produced by the cell.
- ROS and RNS reactive oxygen species
- RNS reactive oxygen species
- melatonin stimulates the production of antioxidant enzymes such as catalase and superoxide dismutase and is involved in DNA repair. By optimizing the functioning of the mitochondria, melatonin also helps to increase the level of ATP produced by the cell.
- Alterations in the barrier function result from external aggressions such as UV rays. The consequences are major in terms of the loss of cell cohesion and mechanical integrity. Certain enzymes involved in the terminal phases of keratinocyte differentiation play a key role in protection against UV rays. Changes in the expression and / or activity of these enzymes have important consequences for the integrity of the barrier function and homeostasis of the skin.
- Example 1 Preparation of an extract of lavender (Lavandula angustifolia) of the Lamiaceae family, enriched in small RNA
- 3% of dried lavender flowers and stems bearing the flowers are ground in the form of powder with a particle size ranging from 500 ⁇ m to 1 mm, preferably at 800 ⁇ m, i.e. the equivalent of 30 g of powder of dried lavender flowers in 968 g of distilled water. Then 2 g / L or 3 mM of phytic acid are added. The pH is adjusted to 10.8 for optimal enrichment of the extract in RNA of small molecular weights. [117] The mixture is then heated for 1 hour at 80 ° C. with stirring.
- diatomaceous earth is added to this mixture to facilitate subsequent separation between the residual solid plant material and the extract (soluble fraction).
- the mixture is then filtered using 30 ⁇ m porosity filters to remove solid matter.
- the pH is then adjusted to pH 7.5 using an HCl solution.
- Sequential filtrations on filters of decreasing porosity are then carried out in order to clarify the plant extract to sterilizing filtration at 0.2 ⁇ m.
- the pH is checked, then it is adjusted to 6.3 with an HCl solution. 6 and 6.5 and preserve the small RNAs in the extract.
- An aqueous extract is obtained having a dry weight of 12.6 g / kg.
- Physico-chemical analysis shows that the extract obtained has a concentration of 3.7 g / kg of total sugars, 1160 g / kg of total organic acids, 1270 mg / kg of total phenolic compounds and 118 mg / kg of RNA of small molecular weights of up to 150 nucleotides in length.
- the extract is then diluted with a physiologically acceptable cosmetic solvent to guarantee better stability and better conservation of the extract over time.
- the dilution is carried out with butylene glycol derived from plants so as to obtain a final concentration of 50% butylene glycol and 50% lavender extract.
- the extract thus diluted then has a dry weight of 6 g / kg, and has a concentration of 1.7 g / kg of total sugars, 570 mg / kg of total organic acids, 620 mg / kg of total phenolic compounds and 45 mg / kg of low molecular weight RNA with a maximum length of 150 nucleotides.
- the total sugar content of the extract was determined by spectrophotometric assay resulting from an adaptation of the assay described by Dubois et al. (1956) (Dubois et al., "Colorimetric method for the determination of sugars and related substances", Anal. Chem., 1956, 28 (3), 350-356).
- This analysis consists of dissolving the raw material in concentrated sulfuric acid and then reacting with phenol to form a colored complex. The absorbance of the complex is read on the spectrophotometer at 490 nm. The sugar content is determined using a standard glucose curve.
- a TLC analysis made it possible to demonstrate that the major sugars present in the extract of the invention are glucose and fructose molecules as well as sugars of high molecular weight (oligo and polysaccharides).
- the total polyphenol content of the lavender extract was determined by the Folin-Ciocalteu spectrophotometric assay method (Singleton et al., Analysis of total phenols and other oxidation substrates and antioxidants using the Folin-Ciocalteu reagent, 1999, 299: 152).
- the polyphenol-like compounds present in the sample react with the Folin-Ciocalteu reagent, oxidation of the reagent gives a blue color.
- the absorbance of the sample is read on the spectrophotometer at 760 nm. The content is expressed in gallic acid equivalents using a gallic acid standard curve.
- the temperature of the column was maintained at 25 ° C and the injection volume was 5 ⁇ L.
- Detection was performed by an ACQUITY Qda (WATERS) mass spectrometer detector with an electrospray ion source in negative mode. The source was set to a capillary voltage of 0.8 kV and a probe temperature of 600 ° C.
- HPLC-MS analysis which makes it possible to quantify and identify the organic acids contained in the extract, shows that only the lavender extract contains different types of organic acids, mainly citric, malic and tartaric acid, as presented in FIG. 1. HPLC-MS analysis shows that these organic acids are present neither in the floral water of true lavender nor in the essential oil of true lavender.
- RNAs The quantification of low molecular weight RNAs was performed by a miniaturized electrophoresis technique on microfluidic chips specific for nucleic acid analysis such as that of low molecular weight RNAs (Bioanalyzer 2100®, Agilent). This method makes it possible to determine the size and concentration of nucleic acids contained in an extract from a few microliters. The result is presented as a graph with an arbitrary fluorescence unit (FU) on the ordinate and the number of nucleotides (nt) on the abscissa. An internal marker is added to each analysis (peak at 25 nt in Figure 2), and serves as an internal control to validate the proper conduct of the analysis.
- FU arbitrary fluorescence unit
- nt nucleotides
- Figure 2 shows the analysis of small molecular weight RNAs by the 2100 Bioanalyzer.
- A lavender extract according to Example 1.
- B conventional lavender extract according to Example 2.
- Bioanalyzer analysis shows that the method described in the present invention extracts low molecular weight RNAs from lavender, as shown in Figure 2A.
- Figure 2A shows that the RNAs present in the lavender extract of the invention have molecular weights ranging from greater than 25 to about 150 nucleotides.
- a conventional extraction process such as the maceration described below in Example 2 does not make it possible to extract the RNAs of small molecular weights (FIG. 2B).
- the analysis also made it possible to demonstrate that there are no these molecules either in the floral water or in the essential oil. In addition, this analysis makes it possible to demonstrate the absence of DNA in the extract.
- VOC volatile odorous compounds
- Example 2 preparation of a lavender macerate In order to compare a so-called classic extraction with the extract of the invention, a lavender macerate was carried out, using the same quantity of dried lavender flowers of the species Lavandula angustifolia as in Example 1, either 3% crushed dried lavender flowers put in distilled water. The mixture is then heated for 1 h at 80 ° C, then the mixture is filtered by a first filtration with a large porosity of 30 ⁇ m in order to remove the solid residual plant material from the liquid part, then by sequential filtration of decreasing porosity until 0.2 ⁇ m. The purpose of this process is to prepare a control extract in order to obtain comparative analytical data with respect to the lavender extract obtained by the process of the invention. The results obtained are illustrated in FIG. 2B and in the text of the application.
- Example 3 Evaluation of the Lavandula angustifolia extract of Example 1 on reactive oxygen species after application of visible light stress on normal human keratinocytes:
- the aim of this study is to show the effect of the lavender extract prepared according to Example 1 on the decrease in reactive oxygen species generated by visible light stress. This type of light between 400 and 700 nm is intended to mimic daylight. Reactive oxygen species are involved in different mechanisms of protein and DNA damage, linked to skin aging.
- ROS reactive oxygen species
- Lavender extract has shown antioxidant activity, directed against reactive oxygen species at the mitochondrial level. This activity has been shown to be superior to that obtained with a lavender extract obtained from conventional maceration.
- Example 4 Evaluation of the extract from Example 1 on DNA damage in normal human melanocytes exposed to UVB stress:
- Genomic instability can be defined as all the chemical changes in DNA that occur in different processes and can accumulate over time. DNA damage is a major component of photoaging. In the present study, we are interested in the damage created by UVB in melanocytes.
- Pyrimidine dimers result from a direct effect of UVB on pyrimidine bases in DNA. There is formation of cyclobutane pyrimidine dimers (or CPD for Cyclobutane Pyrimidine Dimer) which is the most common DNA damage induced by UVB. In melanocytes, CPDs continue to be generated more than 3 hours after exposure to UVB. They are called “dark CPDs" and are caused by the chemexcitation of melanin, leading to energy transfer to DNA.
- the melanocytes Under non-irradiated conditions, the melanocytes do not exhibit CPDs. Their formation is induced as a result of UVB stress.
- the application of the extract of Example 1 on the melanocytes made it possible to reduce the induction of "dark CPDs" by UVB by -37% (highly significant according to Student's t test compared to irradiated cells. untreated). Under the same conditions and at an equal concentration of 0.1%, the lavender macerate obtained according to Example 2 did not have a significant effect.
- the extract from Example 1 decreased "dark CPDs" produced in melanocytes by UVB stress. Through this activity, lavender extract has been shown to benefit in reducing DNA damage, contributing to the skin's repair mechanisms overnight.
- Example 5 Evaluation of the extract of Example 1 on the melatonin synthesis pathway in ex vivo skin biopsies and human hair follicles:
- the aim of this experiment is to demonstrate an effect of the extract of Example 1 on the synthesis of melatonin in biopsies of human skin in culture.
- This evaluation includes two markers: 1 - the enzyme AANAT (Aralkylamine N-Acetyltransferase or serotonin N-acetyl transferase or timezyme) which catalyzes the N-acetylation of serotonin to N-acetylserotonin, the final step in the synthesis of melatonin, 2 - the evaluation of melatonin itself.
- the AANAT enzyme controls the day / night rate of melatonin production at the level of the pineal gland. As melatonin is also synthesized locally in the skin, we wanted to follow its synthesis in response to the application of lavender extract.
- the AANAT enzyme and melatonin are evaluated by indirect immunofluorescence on skin biopsies, previously treated with topical application of lavender extract for 48 hours (twice a day).
- the extract of Example 1 diluted to 0.5% (volume / volume dilution) in the culture medium was contacted with human hair follicles, isolated from scalp biopsies.
- Control biopsies incubated in parallel under the same conditions, as well as control hair follicles without addition of lavender extract, receive the placebo (Phosphate Buffer Saline, PBS). At the end of the incubation, the biopsies and the hair follicles are fixed and embedded in paraffin for the realization of histological sections.
- the detection of the enzyme AANAT and of melatonin is carried out by incubation with the respective antibodies: anti-AANAT (Invitrogen) and anti-melatonin (Abnova, Cliniscience). After an hour and a half of incubation followed by rinses, the sections are incubated in the presence of the secondary anti-rabbit antibody coupled to a fluorophore (Alexa Fluor® 488, Invitrogen). The sections are then examined under an Epifluorescence microscope (Zeiss Axiovert 200M microscope). The expression of collagen I is then observed and quantified by image analysis (Volocity® image analysis software, Improvision).
- the extract from Example 1 showed activity on melatonin production in ex vivo skin biopsies and in hair follicles. This increase is related to an increase in the enzyme AANAT, which is increased in expression in the pineal gland during the transition from day to night.
- the properties of melatonin are linked to cell damage repair activities, especially at the DNA level and due to its antioxidant activity.
- the increase in melatonin in the skin by lavender extract therefore appears to be beneficial for the damage repair processes of the skin overnight.
- the increase in melatonin in the hair follicle indicates a beneficial effect on the physiology of the hair follicle, since melatonin is associated with the growth phase of the hair.
- Example 6 Evaluation of the lightening potential of the extract of Example 1 on ex vivo skin biopsies:
- the aim of this study is to evaluate the lightening potential of the extract of Example 1 on ex vivo skin biopsies, using the histological staining of Fontana-Masson melanin, based on the reduction of a solution of ammoniacal silver nitrate in metallic silver. The color obtained reveals the melanin content and is quantified by image analysis.
- Ex vivo human skin biopsies are cultured and treated with the extract of Example 1 at 0.5% (volume / volume dilution) and 1% (volume / volume dilution) for 48 hours. After treatment, the biopsies are fixed for histological analysis and embedded in paraffin. After dewaxing, the sections are incubated with the ammoniacal silver nitrate solution at 60 ° C. for 10 minutes. After rinsing, they are treated with 5% sodium thiosulphate for 2 minutes, then rinsed again and mounted for examination under an Eclipse E600 microscope (Nikon). Photos are taken with the camera Qlmaging Retiga 2000R Fast1394 and analyzed by Q-Capture Pro 7 software (Qlmaging).
- Example 7 Formula of a rich cream
- phase C is added to the main vessel and homogenize for 10 minutes;
- phase E at 60 ° C. Mix well to homogenize for 10 minutes;
- phase H sprinkle Natrosol TM in water at room temperature and homogenize while heating to 60 ° C;
- phase H at 30 ° C. Mix well to homogenize
- composition is thus in the form of a pink buttercream, with a pH between 4.90 and 5.40 and a viscosity (OD) of 160,000 - 210,000 cps (Brookfield RVT / Spindle D / 5 RPM / 1 minute / 25 ° C).
- phase D in a separate beaker and add to the main vessel at 25 ° C;
- phase E is added to the main container and mix well;
- composition is thus in the form of a cream gel with scintillating green effects, with a pH between 5.30 and 5.80 and a viscosity (OD) of 70,000 - 100,000 cps (Brookfield RVT / Spindle C / 5 RPM / 1 minute / 25 ° C).
- Example 9 Formula of a Serum
- composition is thus in the form of a smooth, semi-opaque serum, with a pH between 5.75 and 6.25 and a viscosity (OD) of 1.100 - 1.400 cps (Brookfield RVT / spindle 3/20 rpm / 25 ° C / 1 minute).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a method for obtaining an aqueous extract of lavender enriched in small RNAs being a maximum of 150 nucleotides in length, sugars, phenolic compounds and organic acids, and free of DNA, obtained by the following method: the aerial parts of lavender are placed in water; phytic acid is added at a pH of between 10 and 11; the pH of the obtained mixture is then adjusted to a value between 6 and 8, and the obtained mixture is purified. The invention also relates to cosmetic compositions comprising such an extract and their cosmetic uses for protecting the skin from external aggressions and oxidation, combating the signs of skin ageing, increasing photoprotection, lightening the skin, improving hydration, improving the barrier function, soothing the skin or improving the biological mechanisms associated with skin repair during the night.
Description
Description Description
Titre de l'invention : PROCEDE D’OBTENTION D’UN EXTRAIT AQUEUX DE LAVANDE, COMPOSITIONS COMPRENANT UN TEL EXTRAIT ET LEURS UTILISATIONSTitle of the invention: PROCESS FOR OBTAINING AN AQUEOUS LAVENDER EXTRACT, COMPOSITIONS INCLUDING SUCH EXTRACT AND THEIR USES
COSMETIQUES COSMETICS
Domaine technique Technical area
[1] L'invention concerne le domaine de la cosmétique et plus particulièrement des ingrédients actifs d’origine naturelle entrant dans la préparation de formulation cosmétique pour améliorer l’aspect de la peau ou la protéger. [1] The invention relates to the field of cosmetics and more particularly to active ingredients of natural origin used in the preparation of cosmetic formulation for improving the appearance of the skin or protecting it.
[2] L'invention concerne un procédé d’obtention d’un extrait aqueux de lavande ainsi que l’extrait enrichi en petits ARN, en sucres, en composés phénoliques, en acides organiques obtenus par le procédé, les compositions cosmétiques comprenant de tels extraits et leurs utilisations cosmétiques pour le soin de la peau, du cuir chevelu et des phanères et plus particulièrement pour protéger la peau des agressions externes et de l’oxydation, lutter contre les signes du vieillissement cutané, augmenter la photoprotection, éclaircir la peau, améliorer l’hydratation de la peau, renforcer la fonction barrière, apaiser la peau ou encore pour améliorer les mécanismes biologiques associés à la réparation de la peau pendant la nuit. [2] The invention relates to a process for obtaining an aqueous extract of lavender as well as the extract enriched in small RNA, in sugars, in phenolic compounds, in organic acids obtained by the process, the cosmetic compositions comprising such extracts and their cosmetic uses for the care of the skin, scalp and integuments and more particularly to protect the skin from external aggressions and oxidation, fight against the signs of skin aging, increase photoprotection, lighten the skin, improve skin hydration, strengthen the barrier function, soothe the skin or to improve the biological mechanisms associated with skin repair at night.
Arrière-plan technique de l’invention Technical background of the invention
[3] Les plantes du genre Lavandula, communément appelées lavandes, forment un groupe de 47 espèces. Parmi les espèces les plus connues et utilisées on trouve Lavandula angustifolia, aussi appelée lavande vraie, une espèce sauvage originaire de Provence (sud-est de la France), ou encore le lavandin, un hybride issu du croisement de la lavande vraie et de la lavande aspic. [3] Plants of the genus Lavandula, commonly known as lavender, form a group of 47 species. Among the best known and used species are Lavandula angustifolia, also called true lavender, a wild species native to Provence (south-eastern France), or lavandin, a hybrid resulting from the crossing of true lavender and lavender aspic.
[4] La lavande vraie est largement utilisée pour la production d'huiles essentielles en Europe, en Afrique du Nord, au Moyen-Orient et en Asie, en particulier pour l’industrie du parfum. [4] True lavender is widely used for the production of essential oils in Europe, North Africa, the Middle East and Asia, particularly for the perfume industry.
[5] L’huile essentielle (HE) est généralement obtenue par hydrodistillation. Les fleurs préalablement séchées sont soumises à un courant de vapeur d’eau qui entraîne
les constituant volatils ou solubles puis est ensuite recondensé pour obtenir un hydrolat (ou eau florale) et un surnageant comprenant les parties lipidiques de la plante et constituant l’huile essentielle. [5] Essential oil (ET) is generally obtained by hydrodistillation. The previously dried flowers are subjected to a stream of water vapor which entrains the volatile or soluble constituents are then recondensed to obtain a hydrosol (or floral water) and a supernatant comprising the lipid parts of the plant and constituting the essential oil.
[6] Les HE de lavande sont très parfumées et comprennent majoritairement des monoterpènes volatils comme le linalol et l'acétate de linalyle. Dans IΉE de lavande vraie, tous deux sont présents à environ 30%. L’HE de lavande est particulièrement reconnue pour ses propriétés sédatives, antalgiques, analgésiques, anti-inflammatoires, antiseptiques et antibactériennes. Elle est également antispasmodique et décongestionnante et indiquée pour apaiser les affections cutanées et favoriser la cicatrisation. L’HE de lavande est également indiquée pour améliorer les troubles du sommeil et les tensions diverses (anxiété, stress, etc.). [6] Lavender EOs are very fragrant and predominantly include volatile monoterpenes such as linalool and linalyl acetate. In true lavender IΉE, both are present at about 30%. Lavender EO is particularly recognized for its sedative, analgesic, analgesic, anti-inflammatory, antiseptic and antibacterial properties. It is also antispasmodic and decongestant and indicated to soothe skin conditions and promote healing. Lavender EO is also indicated to improve sleep disorders and various tensions (anxiety, stress, etc.).
[7] Les eaux florales de lavande contiennent moins de quelques pour cent de composés volatils organiques semblables à ceux de l’huile essentielle, ainsi que les composés hydrosolubles de la plante. L’eau florale a les mêmes propriétés que l’huile essentielle de lavande, mais plus atténuées à cause des concentrations plus faibles en composés terpéniques. [7] Lavender floral waters contain less than a few percent of essential oil-like volatile organic compounds, as well as the water-soluble compounds of the plant. Floral water has the same properties as lavender essential oil, but more attenuated due to the lower concentrations of terpene compounds.
[8] L’utilisation très limitée en cosmétique des huiles essentielles et eaux florales de lavande est en partie due à la présence majoritaire de molécules terpéniques connues pour leurs effets irritants sur la peau. Le linalol a par exemple été reconnu comme potentiellement allergisant et l’utilisation d’huile essentielle de lavande est déconseillée aux femmes enceintes et aux enfants de moins de 12 ans. [8] The very limited cosmetic use of lavender essential oils and floral waters is in part due to the majority presence of terpene molecules known to have irritant effects on the skin. Linalool, for example, has been recognized as a potentially allergenic and the use of lavender essential oil is not recommended for pregnant women and children under 12 years old.
[9] La plupart des autres méthodes d’extraction de lavande décrites dans l’art antérieur utilisent des solvants organiques de type apolaire qui permettent d’extraire principalement les composés odorants volatiles (CN10338583,[9] Most of the other lavender extraction methods described in the prior art use non-polar organic solvents which mainly extract volatile odorous compounds (CN10338583,
JP11199469) ou un fluide supercritique (KR2015042999). Dans ce dernier cas, l’extrait obtenu est riche en polyphénols et flavonoïdes, mais ne contient pas d’autres composés d’intérêt comme les acides aminés, les acides organiques ou les protéines. De plus, les acides phénoliques ne sont pas extraits par ce type de technique, en effet ces molécules sont principalement extraites dans un solvant polaire et idéalement avec de l’eau.
[10] Les consommateurs de produits cosmétiques souhaitent utiliser des formules aussi naturelles que possibles, tout en présentant une efficacité aussi importante voire meilleure que les produits synthétiques. JP11199469) or a supercritical fluid (KR2015042999). In the latter case, the extract obtained is rich in polyphenols and flavonoids, but does not contain other compounds of interest such as amino acids, organic acids or proteins. In addition, phenolic acids are not extracted by this type of technique, in fact these molecules are mainly extracted in a polar solvent and ideally with water. [10] Consumers of cosmetic products want to use formulas that are as natural as possible, while exhibiting as great or even better efficacy than synthetic products.
[11] Malgré les différents produits cosmétiques anti-âge déjà sur le marché, le besoin de nouveaux ingrédients cosmétiques efficaces d’origine naturelle est de plus en plus fort. [11] Despite the various anti-aging cosmetic products already on the market, the need for new and effective cosmetic ingredients of natural origin is growing.
[12] Un problème que se propose de résoudre l’invention est de proposer un nouvel extrait aqueux de lavande répondant à l’exigence du marché cosmétique actuel concernant les critères de naturalité et présentant néanmoins une efficacité biologique remarquable. [12] One problem which the invention proposes to solve is to provide a new aqueous extract of lavender meeting the requirements of the current cosmetic market concerning the criteria of naturalness and nevertheless exhibiting remarkable biological efficacy.
[13] Un autre problème que se propose de résoudre l’invention est de proposer un nouvel extrait aqueux de lavande ne représentant pas les défauts des extraits actuellement connus, à savoir une forte odeur, une instabilité des HE dans les formules pour application topique, ou encore un caractère irritant ou allergénique due à la présence de molécules terpéniques telles que le linalol. [13] Another problem which the invention proposes to solve is to provide a new aqueous extract of lavender which does not represent the defects of the extracts currently known, namely a strong odor, an instability of the EOs in the formulas for topical application, or else an irritant or allergenic nature due to the presence of terpene molecules such as linalool.
[14] Un problème que se propose encore de résoudre l’invention est de proposer un nouvel extrait aqueux de lavande enrichi en composés connus pour leur efficacité sur la peau comme les petits ARN, les sucres, les composés phénoliques et les acides organiques. [14] A problem which the invention still proposes to solve is to provide a new aqueous extract of lavender enriched with compounds known for their effectiveness on the skin such as small RNAs, sugars, phenolic compounds and organic acids.
[15] Les inventeurs ont développé un nouvel extrait de fleur de lavande spécifiquement enrichi en petits ARN, en sucres, en composés phénoliques et en acides organiques, et ne présentant pas les inconvénients des procédés de l’art antérieur cité, comme par exemple l’utilisation de détergents et de solvants potentiellement toxiques en cosmétique. [15] The inventors have developed a new extract of lavender flower specifically enriched with small RNAs, sugars, phenolic compounds and organic acids, and which does not have the drawbacks of the methods of the prior art cited, such as, for example, use of potentially toxic detergents and solvents in cosmetics.
[16] L’extrait ainsi obtenu peut être utilisé en cosmétique pour le soin de la peau, du cuir chevelu et des phanères et plus particulièrement pour protéger la peau des agressions externes et de l’oxydation, lutter contre les signes du vieillissement cutané, augmenter la photoprotection, éclaircir la peau, améliorer l’hydratation de la peau, renforcer la fonction barrière ou encore apaiser la peau. [16] The extract thus obtained can be used in cosmetics for the care of the skin, scalp and integuments and more particularly to protect the skin from external aggressions and oxidation, to fight against the signs of skin aging, increase photoprotection, lighten the skin, improve skin hydration, strengthen the barrier function or even soothe the skin.
Résumé de l’invention
[17] L’invention a pour premier objet un procédé d’obtention d’un extrait aqueux de parties aériennes de lavande, comprenant les étapes suivantes: a) on met en présence les parties aériennes de lavande avec de l’eau ; b) on ajoute de l’acide phytique à une concentration comprise entre 1 et 10 mM dans le mélange obtenu en a) à un pH compris entre 10 et 11 ; c) on ajuste ensuite le pH du mélange obtenu en b) à une valeur comprise entre 6 et 8 ; d) on purifie le mélange obtenu en c) de manière à éliminer la matière végétale solide résiduelle et obtenir un extrait brut aqueux purifié ; et e) on contrôle le pH et on le réajuste si nécessaire à une valeur comprise entre 6 et 8, préférentiellement entre 6 et 6,5. Summary of the invention [17] The first subject of the invention is a process for obtaining an aqueous extract of aerial parts of lavender, comprising the following steps: a) the aerial parts of lavender are brought into contact with water; b) phytic acid is added at a concentration of between 1 and 10 mM in the mixture obtained in a) at a pH of between 10 and 11; c) the pH of the mixture obtained in b) is then adjusted to a value between 6 and 8; d) the mixture obtained in c) is purified so as to eliminate the residual solid plant material and to obtain a purified aqueous crude extract; and e) the pH is checked and it is readjusted if necessary to a value between 6 and 8, preferably between 6 and 6.5.
[18] De plus, l’invention a pour deuxième objet un extrait aqueux de parties aériennes de lavande enrichi en petits ARN d’une longueur d’au maximum 150 nucléotides, en sucres, en composés phénoliques et en acides organiques, dépourvu d’ADN, susceptible d’être obtenu par le procédé de l’une des revendications 1 à 5, caractérisé en ce qu’il comprend en poids du poids total de l’extrait, 10 à 30 g/kg de poids sec, contenant 2 à 10 g/kg de sucres, 100 à 1500 mg/kg d’acides organiques, 500 à 2000 mg/kg de composés phénoliques et 40 à 200 mg/kg d’ARN de petits poids moléculaires d’une longueur d’au maximum 150 nucléotides. [18] In addition, a second subject of the invention is an aqueous extract of aerial parts of lavender enriched in small RNA with a length of at most 150 nucleotides, in sugars, in phenolic compounds and in organic acids, devoid of DNA, obtainable by the process of one of claims 1 to 5, characterized in that it comprises, by weight of the total weight of the extract, 10 to 30 g / kg of dry weight, containing 2 to 10 g / kg of sugars, 100 to 1500 mg / kg of organic acids, 500 to 2000 mg / kg of phenolic compounds and 40 to 200 mg / kg of low molecular weight RNA up to a length of 150 nucleotides.
[19] L’invention a pour troisième objet une composition cosmétique comprenant, en tant qu’ingrédient actif, une quantité efficace de l’extrait de l’une des revendications 6 ou 7, et un milieu physiologiquement acceptable. [19] The third object of the invention is a cosmetic composition comprising, as an active ingredient, an effective amount of the extract of one of claims 6 or 7, and a physiologically acceptable medium.
[20] L’invention a pour quatrième objet l’utilisation cosmétique de la composition de l’invention, pour le soin de la peau, du cuir chevelu et des phanères, plus particulièrement pour protéger la peau des agressions externes et de l’oxydation, lutter contre les signes du vieillissement cutané, augmenter la photoprotection, éclaircir la peau, améliorer l’hydratation de la peau, renforcer la fonction barrière, apaiser la peau, ou encore pour améliorer les mécanismes biologiques associés à la réparation de la peau pendant la nuit. [20] A fourth subject of the invention is the cosmetic use of the composition of the invention, for the care of the skin, the scalp and integuments, more particularly for protecting the skin from external attacks and from oxidation. , fight against the signs of skin aging, increase photoprotection, lighten the skin, improve skin hydration, strengthen the barrier function, soothe the skin, or even to improve the biological mechanisms associated with the repair of the skin during night.
Brève description des dessins
[21] L’invention et les avantages qui en découlent seront mieux compris à la lecture de la description et des modes de réalisation non limitatifs qui suivent, illustrés au regard des figures annexées dans lesquelles : Brief description of the drawings [21] The invention and the advantages which result therefrom will be better understood on reading the description and the non-limiting embodiments which follow, illustrated with reference to the appended figures in which:
[22] [Fig. 1] Caractérisation des acides organiques par analyse HPLC-MS[22] [Fig. 1] Characterization of organic acids by HPLC-MS analysis
[23] [Fig. 2] Analyse des ARN de petits poids moléculaires par le Bioanalyseur 2100. A : extrait de lavande obtenu selon le procédé de l’invention - B : extrait conventionnel de lavande. [23] [Fig. 2] Analysis of RNAs of small molecular weight by the Bioanalyzer 2100. A: lavender extract obtained according to the process of the invention - B: conventional lavender extract.
Description détaillée de l’invention Detailed description of the invention
Définitions Definitions
[24] Tous les termes utilisés dans la présente description ont le sens le plus largement connus sauf mention contraire. Pour les besoins de l’invention les termes suivants sont définis comme suit : [24] All the terms used in the present description have the most widely known meaning unless otherwise specified. For the purposes of the invention, the following terms are defined as follows:
[25] On entend par « lavande » toutes les espèces du genre Lavandula, ainsi que leurs hybrides (tel que le lavandin). [25] By "lavender" is meant all species of the genus Lavandula, as well as their hybrids (such as lavandin).
[26] On entend par « parties aériennes » les tiges et fleurs de lavande. Les graines sont comprises dans les « parties aériennes » au sens de l’invention. [26] By "aerial parts" is meant the stems and flowers of lavender. The seeds are included in the "aerial parts" within the meaning of the invention.
[27] Dans le cours de la présente description, les termes « parties aériennes » et « fleurs » seront utilisés indifféremment pour désigner les fleurs et les tiges les plus fines portant les fleurs. [27] In the course of the present description, the terms “aerial parts” and “flowers” will be used interchangeably to designate the flowers and the thinnest stems bearing the flowers.
[28] Par « petits ARN » ou « ARN de petits poids moléculaires », ou « petits ARN d’une longueur d’au maximum 150 nucléotides » on entend des ARN (acides ribonucléiques) non codants, de petit poids moléculaire, d’une longueur d’au maximum 150 nucléotides, tels que tous types de petits ARN non messagers, simples et/ou doubles brins, par exemple les micro-ARN, les ARN interférents, les introns, les petits ARN nucléaires ou encore tout fragment d’ARN. L’analyse par électrophorèse montre que les petits ARN présents dans l’extrait de lavande de l’invention ont des poids moléculaires variés compris approximativement entre 30 et 150 nucléotides.
[29] Par « acides organiques » on entend les acides a-hydroxylés (ou AHA), c’est- à-dire des acides carboxyliques dérivés de sucres de fruits ou de plantes, tels que les acides glycolique, malique, citrique, tartrique, succinique et uronique. [28] By "small RNA" or "RNA of small molecular weight", or "small RNA of a maximum length of 150 nucleotides" is meant non-coding RNAs (ribonucleic acids), of low molecular weight, of a length of at most 150 nucleotides, such as all types of small non-messenger RNAs, single and / or double strands, for example microRNAs, interfering RNAs, introns, small nuclear RNAs or even any fragment of RNA. Electrophoresis analysis shows that the small RNAs present in the lavender extract of the invention have varied molecular weights of approximately between 30 and 150 nucleotides. [29] By "organic acids" is meant α-hydroxy acids (or AHAs), that is to say carboxylic acids derived from fruit or plant sugars, such as glycolic, malic, citric or tartaric acids. , succinic and uronic.
[30] Par composés phénoliques (ou polyphénols) on entend les molécules d’origine végétale qui possèdent un cycle aromatique portant un ou plusieurs groupements hydroxyles, tels que les acides phénoliques, les flavonoïdes ou leurs dérivés. Les composés polyphénoliques sont reconnus pour être de puissantes molécules antioxydantes. [30] By phenolic compounds (or polyphenols) is meant molecules of plant origin which have an aromatic ring carrying one or more hydroxyl groups, such as phenolic acids, flavonoids or their derivatives. Polyphenolic compounds are known to be powerful antioxidant molecules.
[31] Par « sucres » on entend les monosaccharides et plus particulièrement le glucose et le fructose ainsi que les oligo et polysaccharides. [31] The term “sugars” means monosaccharides and more particularly glucose and fructose as well as oligo and polysaccharides.
[32] Par « phytomolécules d’intérêt », on entend l’ensemble des molécules présentes dans l’extrait de lavande de l’invention et notamment, les petits ARN d’une longueur d’au maximum 150 nucléotides, les sucres, les composés phénoliques et les acides organiques. [32] The term "phytomolecules of interest" means all of the molecules present in the lavender extract of the invention and in particular, small RNAs with a length of at most 150 nucleotides, sugars, phenolic compounds and organic acids.
[33] Quand une gamme de valeur est décrite, les bornes de cette gamme doivent être comprises comme incluant explicitement toutes les valeurs intermédiaires de la gamme. Par exemple, une gamme de valeur comprise entre 1% et 10% doit être comprise comme incluant 1 %, 2 %, 3 %, 4 %, 5 %, 6 %, 1 %, 8 %, 9 %, et 10 %, ainsi que toutes les valeurs décimales entre 1 % et 10 %. [33] When a range of values is described, the bounds of that range should be understood as explicitly including all intermediate values of the range. For example, a range of values between 1% and 10% should be understood as including 1%, 2%, 3%, 4%, 5%, 6%, 1%, 8%, 9%, and 10%, as well as all decimal values between 1% and 10%.
[34] Les valeurs numériques en pourcentage sont des pourcentages en poids, c’est-à-dire le poids d’un composé par rapport au poids total du mélange envisagé, sauf spécifié autrement. [34] The numerical values in percent are percentages by weight, that is to say the weight of a compound compared to the total weight of the mixture envisaged, unless specified otherwise.
[35] Les compositions décrites dans la présente demande peuvent [35] The compositions described in the present application can
« comprendre », « consister en » ou « consister essentiellement en », les composés essentiels ou les ingrédients optionnels. "Include", "consist of" or "consist essentially of" the essential compounds or optional ingredients.
[36] « Consister essentiellement en » signifie que la composition ou le composant peut inclure des ingrédients additionnels, mais seulement si les ingrédients additionnels ne modifient pas les caractéristiques de bases ou les nouvelles caractéristiques de la composition ou de l’utilisation décrite dans la présente demande.
[37] Un « milieu physiologiquement acceptable » désigne un véhicule adapté pour une mise en contact avec les couches externes de la peau ou des muqueuses, sans toxicité, irritation, réponse allergique indue et similaire ou réaction d’intolérance, et proportionné à un rapport avantage/risque raisonnable. [36] "Consist essentially of" means that the composition or component may include additional ingredients, but only if the additional ingredients do not modify the basic characteristics or the new characteristics of the composition or the use described herein. request. [37] A "physiologically acceptable medium" means a vehicle suitable for contact with the outer layers of the skin or mucous membranes, without toxicity, irritation, undue allergic and similar response or intolerance reaction, and proportionate to a ratio. reasonable benefit / risk.
[38] Par « application topique » on désigne le fait d’appliquer ou d’étaler l’extrait aqueux enrichi en petits ARN d’une longueur d’au maximum 150 nucléotides, en sucres, en composés phénoliques et en acides organiques selon l’invention, ou une composition le contenant, à la surface de la peau ou d’une muqueuse. [38] By "topical application" is meant the fact of applying or spreading the aqueous extract enriched in small RNA with a length of at most 150 nucleotides, in sugars, in phenolic compounds and in organic acids according to invention, or a composition containing it, on the surface of the skin or of a mucous membrane.
[39] « Peau » désigne la peau du visage, notamment le contour des yeux et la bouche, le nez, le front, le cou, les mains, mais aussi la peau de l’ensemble du corps. [39] "Skin" refers to the skin of the face, including the area around the eyes and mouth, nose, forehead, neck, hands, but also the skin of the whole body.
[40] « Cuir chevelu » désigne la peau recouvrant le crâne, incluant les follicules pileux et les espaces cutanés inter-folliculaires. [40] "Scalp" refers to the skin covering the skull, including hair follicles and inter-follicular skin spaces.
[41] « Phanères » désigne chez les produits des follicules pileux (cheveux et poils) ainsi que les ongles, riches en kératine. [41] “Integuments” in products designate hair follicles (hair and body hair) as well as the nails, which are rich in keratin.
[42] On entend par « renforcer la fonction barrière » que les propriétés de protection de la peau vis-à-vis des agressions extérieures (radiations UV, lumière visible ou infrarouge, pollution, microorganismes, etc.) sont améliorées. [42] The term “reinforcing the barrier function” means that the protective properties of the skin against external aggressions (UV radiation, visible or infrared light, pollution, microorganisms, etc.) are improved.
[43] On entend par « apaiser la peau » diminuer les réactions d’irritation qui se manifestent par une sensation d’inconfort, pouvant s’accompagner de rougeurs. [43] "Soothing the skin" is understood to reduce the irritant reactions that manifest as a feeling of discomfort, which may be accompanied by redness.
[44] « Eclaircir la peau » signifie diminuer l’intensité de la couleur de la peau liée au contenu en mélanine de l’épiderme, soit de manière homogène, soit de manière localisée en agissant sur des désordres pigmentaires, tels que les tâches de senescence ou lentigo séniles. [44] "Lightening the skin" means reducing the intensity of the color of the skin linked to the melanin content of the epidermis, either homogeneously or locally by acting on pigment disorders, such as dark spots. senescence or senile lentigo.
[45] Par « quantité efficace » on désigne la quantité minimum d’extrait selon l’invention qui est nécessaire pour obtenir au moins une des activités biologiques recherchées, en particulier pour présenter une activité antioxydante vis-à-vis des espèces réactives de l’oxygène, augmenter la mélatonine ou diminuer la mélanine, ou tout autre marqueur biologique étudié, sans que cette quantité soit toxique.
[46] Par « hydratation de la peau », on entend le contenu et la répartition en eau des couches supérieures de l’épiderme. [45] By "effective amount" is meant the minimum amount of extract according to the invention which is necessary to obtain at least one of the desired biological activities, in particular to exhibit an antioxidant activity vis-à-vis the reactive species of l. oxygen, increase melatonin or decrease melanin, or any other biological marker studied, without this quantity being toxic. [46] By “skin hydration” is meant the water content and distribution of the upper layers of the epidermis.
[47] On entend par « amélioration de l’hydratation cutanée », toutes améliorations des modifications de l’aspect extérieur de la peau dues à la déshydratation comme, par exemple, la sécheresse, les tiraillements et l’inconfort, que cet état soit lié à des facteurs internes ou externes, tels que des conditions environnementales défavorables. [47] “Improvement of skin hydration” means any improvement in changes in the external appearance of the skin due to dehydration such as, for example, dryness, tightness and discomfort, whether this condition is related to internal or external factors, such as adverse environmental conditions.
[48] Par « signes du vieillissement cutané » on entend toutes modifications de l'aspect extérieur de la peau dues au vieillissement comme, par exemple, les rides et ridules, les crevasses, les poches sous les yeux, les cernes, le flétrissement, la perte d'élasticité, de fermeté et/ou de tonus de la peau, mais également toutes modifications internes de la peau qui ne se traduisent pas systématiquement par un aspect extérieur modifié comme, par exemple, l’amincissement de la peau, ou toutes dégradations internes de la peau consécutives à des stress environnementaux tels que la pollution et les rayonnements solaires incluant les UV. [48] By "signs of skin aging" is meant any changes in the external appearance of the skin due to aging such as, for example, fine lines and wrinkles, cracks, bags under the eyes, dark circles, wilting, loss of elasticity, firmness and / or tone of the skin, but also any internal skin changes that do not systematically result in a modified external appearance such as, for example, thinning of the skin, or all internal degradation of the skin resulting from environmental stresses such as pollution and solar radiation including UV rays.
[49] Par « signes du vieillissement cutané » on entend également les désordres pigmentaires tels que le lentigo sénile ou lentigo solaire. [49] The term “signs of skin aging” also means pigmentary disorders such as senile lentigo or solar lentigo.
[50] Par « agressions externes » on entend les rayonnements solaires, incluant la lumière visible, les rayonnements UV et infrarouges, la pollution, pouvant provenir de l’atmosphère ambiante à l’extérieur ou à l’intérieur des habitations et incluant des particules de différentes tailles (10 pm pour les PM 10, 2,5 pm pour les PM 2,5, ou inférieur à 100 nm pour les particules ultrafines) ainsi que plusieurs éléments chimiques (composés organiques volatils, hydrocarbures aromatiques polycycliques, métaux lourds...). [50] By "external attacks" we mean solar radiation, including visible light, UV and infrared radiation, pollution, which may come from the ambient atmosphere outside or inside homes and including particles of different sizes (10 µm for PM 10, 2.5 µm for PM 2.5, or less than 100 nm for ultrafine particles) as well as several chemical elements (volatile organic compounds, polycyclic aromatic hydrocarbons, heavy metals. .).
[51] On entend par « améliorer l’aspect de la peau » que le grain de la peau apparaît plus fin, la luminosité plus intense et le teint plus homogène. [51] By "improving the appearance of the skin" we mean that the skin texture appears finer, the luminosity more intense and the complexion more homogeneous.
[52] Il est bien entendu que l’invention concerne les mammifères et plus particulièrement l’être humain. [52] It is understood that the invention relates to mammals and more particularly to humans.
Procédé d’extraction
[53] Les protocoles d’extraction des acides ribonucléiques (ARN) classiquement décrits utilisent des solvants inadaptés à un usage cosmétique (Zumbo, P. 2014 "Phenol-chloroform Extraction", 2014). Ces méthodes visent à obtenir des acides nucléiques (ARN ou ADN ou petits ARN) complètement purifiés, c’est-à-dire exempts de toute autre molécule d’intérêt tels que les métabolites secondaires, vitamines, sucres, peptides, etc. qui peuvent avoir des effets bénéfiques pour la peau et présentent donc un intérêt cosmétique. Extraction process [53] The conventionally described ribonucleic acid (RNA) extraction protocols use solvents unsuitable for cosmetic use (Zumbo, P. 2014 "Phenol-chloroform Extraction", 2014). These methods aim to obtain nucleic acids (RNA or DNA or small RNA) completely purified, that is to say free of any other molecule of interest such as secondary metabolites, vitamins, sugars, peptides, etc. which may have beneficial effects for the skin and are therefore of cosmetic interest.
[54] On connaît également le document FR2831168 qui décrit un procédé d’obtention d’un extrait de plante riche en acides nucléiques (ADN et/ou ARN).[54] Document FR2831168 is also known, which describes a process for obtaining a plant extract rich in nucleic acids (DNA and / or RNA).
Le procédé utilise des enzymes cellulolytiques. The process uses cellulolytic enzymes.
[55] On connaît encore de l’art antérieur les documents de brevet EP1723958 et W003101376 qui décrivent une composition pour application topique comprenant un oligonucléotide d’ARN double brins de synthèse d’une longueur de 12 à 40 nucléotides, de séquence connue ayant une fonction de siARN (« short interfering »). [55] Patent documents EP1723958 and W003101376 are also known from the prior art which describe a composition for topical application comprising a synthetic double-stranded RNA oligonucleotide with a length of 12 to 40 nucleotides, of known sequence having a siRNA function ("short interfering").
[56] On connaît encore le document FR 1502361 (également publié sous le numéro WO2017084958) qui décrit un procédé d’obtention d’un extrait aqueux de plantes, enrichi en acides ribonucléiques (ARN) de petit poids moléculaire, pour préparer des compositions cosmétiques. Le procédé utilise de l’EDTA à une concentration comprise entre 2 et 15 mM. [56] Document FR 1502361 (also published under the number WO2017084958) is also known, which describes a process for obtaining an aqueous extract of plants, enriched with low molecular weight ribonucleic acids (RNA), to prepare cosmetic compositions. . The process uses EDTA at a concentration of between 2 and 15 mM.
[57] L’utilisation d’acide phytique au lieu de l’EDTA présente les avantages suivants : Contrairement à l’EDTA, l’acide phytique est une molécule naturelle présente dans l’enveloppe des graines, comme les céréales et les légumineuses. De ce fait, l’utilisation d’acide phytique permet d’obtenir un extrait de lavande 100 % d’origine naturelle tout en maintenant une bonne efficacité d’extraction des phytomolécules contenues dans la plante. L’efficacité d’extraction des petits ARN ainsi que celles des autres composés présents dans les fleurs de lavande tels que les sucres, les composés phénoliques, ou des acides organiques comme l’acide tartrique, malique ou citrique.
[58] L’invention a ainsi pour premier objet un procédé d’extraction mis en oeuvre pour l’obtention d’un extrait aqueux des parties aériennes, séchées ou fraîches de lavande. [57] Using phytic acid instead of EDTA has the following advantages: Unlike EDTA, phytic acid is a naturally occurring molecule found in the husk of seeds, such as grains and legumes. Therefore, the use of phytic acid makes it possible to obtain a lavender extract that is 100% of natural origin while maintaining good extraction efficiency of the phytomolecules contained in the plant. The efficiency of extracting small RNAs as well as those of other compounds present in lavender flowers such as sugars, phenolic compounds, or organic acids such as tartaric, malic or citric acid. [58] The first subject of the invention is thus an extraction process used to obtain an aqueous extract of the aerial, dried or fresh parts of lavender.
[59] Le procédé d’extraction de l’invention permet d’obtenir un extrait riche en phytomolécules d’intérêt cosmétique tels que les petits ARN d’une longueur d’au maximum 150 nucléotides, les sucres, les composés phénoliques et les acides organiques, en évitant l’utilisation de solvants qui ne sont pas considérés comme des solvants cosmétiques. [59] The extraction process of the invention makes it possible to obtain an extract rich in phytomolecules of cosmetic interest such as small RNAs with a maximum length of 150 nucleotides, sugars, phenolic compounds and acids. organic, avoiding the use of solvents that are not considered cosmetic solvents.
[60] Le procédé de l’invention présente un impact réduit sur l’environnement. [60] The process of the invention has a reduced impact on the environment.
[61] Dans une première étape a) du procédé selon l’invention, on mélange les parties aériennes de lavande avec de l’eau. L’eau utilisée est une eau distillée, déminéralisée ou encore une eau riche en sels minéraux et/ou oligo-éléments. L’eau préférentiellement utilisée est de l’eau distillée. [61] In a first step a) of the process according to the invention, the aerial parts of lavender are mixed with water. The water used is distilled, demineralized water or water rich in mineral salts and / or trace elements. The water preferably used is distilled water.
[62] De préférence les parties aériennes de lavande sont les fleurs de lavande et les petites tiges portant les fleurs. [62] Preferably the aerial parts of lavender are the lavender flowers and the small stems bearing the flowers.
[63] De préférence l’espèce de lavande utilisée est Lavandula angustifolia ou lavande vraie. [63] Preferably the species of lavender used is Lavandula angustifolia or true lavender.
[64] De préférence les parties aériennes de lavande sont sous forme sèche. [64] Preferably the aerial parts of lavender are in dry form.
[65] Préférentiellement, les parties aériennes de lavande sont broyées sous forme de poudre avant d’être mise en présence d’eau dans l’étape a). Le broyage les parties aériennes de lavande est une action mécanique qui permet une meilleure extraction. Le broyage mécanique pour obtenir la matière végétale sous forme de poudre, suivi d'une lyse alcaline en présence d’acide phytique favorise la complète déstructuration des membranes cellulaires et notamment de la membrane nucléaire. Préférentiellement, les parties aériennes de lavande préalablement broyées sous forme de poudre, sont mélangées avec de l’eau, à l’étape a) dans un rapport matière végétale / eau de 3 à 20 % en poids/poids, plus préférentiellement dans un rapport entre 3 et 10 %, par exemple dans un rapport de 3 %, 5 % ou 10 % (poids/poids). [65] Preferably, the aerial parts of lavender are ground into powder form before being placed in the presence of water in step a). Grinding the aerial parts of lavender is a mechanical action that allows better extraction. Mechanical grinding to obtain the plant material in powder form, followed by alkaline lysis in the presence of phytic acid promotes the complete destructuring of cell membranes and in particular of the nuclear membrane. Preferably, the aerial parts of lavender previously ground in powder form are mixed with water, in step a) in a plant material / water ratio of 3 to 20% by weight / weight, more preferably in a ratio between 3 and 10%, for example in a ratio of 3%, 5% or 10% (weight / weight).
[66] On ajoute ensuite dans une étape b) de l’acide phytique dans le mélange obtenu en a). Le pH à cette étape doit être basique, à une valeur comprise entre
10 et 11 et doit donc être ajusté, si besoin, par l’ajout de soude (NaOH). Lors de l’étape b) il est essentiel que le pH soit basique, compris entre 10 et 11. De préférence, le pH est ajusté à une valeur comprise entre 10,5 et 11 . En effet, ce niveau de pH, associé à l’action de l’acide phytique, provoque la déstructuration de la membrane cellulaire, y compris la membrane nucléaire, la lyse des cellules et la dénaturation de l’ADN (les 2 brins de la double hélice sont séparés). L’acide phytique fragilise et déstructure les membranes pecto-cellulosiques des cellules végétales en séquestrant par complexation les ions divalents tels que les ions calcium qui forment des ponts ioniques entre les molécules de pectines entourant les microfibrilles de cellulose. Ceci a pour conséquence de favoriser la libération du contenu cellulaire au cours de l’extraction. L’étape de traitement par l’acide phytique est essentielle pour enrichir l’extrait en ARN de petits poids moléculaires et plus généralement assurer un meilleur rendement d’extraction des autres phytomolécules d’intérêt ; à savoir les sucres, les composés phénoliques et les acides organiques. [66] Phytic acid is then added in step b) to the mixture obtained in a). The pH at this stage should be basic, at a value between 10 and 11 and must therefore be adjusted, if necessary, by adding sodium hydroxide (NaOH). During step b) it is essential that the pH is basic, between 10 and 11. Preferably, the pH is adjusted to a value between 10.5 and 11. Indeed, this pH level, associated with the action of phytic acid, causes the destructuring of the cell membrane, including the nuclear membrane, the lysis of cells and the denaturation of DNA (the 2 strands of the double helix are separated). Phytic acid weakens and destructures the pecto-cellulosic membranes of plant cells by sequestering by complexation the divalent ions such as calcium ions which form ionic bridges between the pectin molecules surrounding the cellulose microfibrils. The consequence of this is to promote the release of the cellular content during the extraction. The step of treatment with phytic acid is essential for enriching the extract in RNA of small molecular weights and more generally ensuring a better yield of extraction of the other phytomolecules of interest; namely sugars, phenolic compounds and organic acids.
[67] Le contrôle du pH montre que celui-ci reste basique et se stabilise entre 9 et[67] The pH control shows that it remains basic and stabilizes between 9 and
11 à la fin de l’étape b). 11 at the end of step b).
[68] Le procédé d’extraction permet d’enrichir l’extrait final en ARN de petit poids moléculaires grâce à l’utilisation d’une solution aqueuse d’extraction contenant notamment un agent chélatant naturel tel que l’acide phytique. L’acide phytique est une molécule naturellement présente dans l’enveloppe des graines, comme les céréales et les légumineuses. L’acide phytique est présent sous forme de sels de calcium ou parfois de magnésium, et il joue un important rôle pour la plante, par exemple, c’est la source principale de phosphore. [68] The extraction process makes it possible to enrich the final extract with low molecular weight RNA through the use of an aqueous extraction solution containing in particular a natural chelating agent such as phytic acid. Phytic acid is a molecule found naturally in the husk of seeds, such as grains and legumes. Phytic acid is present in the form of calcium salts or sometimes magnesium, and it plays an important role for the plant, for example, it is the main source of phosphorus.
[69] De manière préférée, l’acide phytique utilisé est une poudre d’acide phytique sous forme de sel de sodium à une concentration préférentiellement comprise entre 1 et 10 mM, préférentiellement entre 1 et 5 mM et plus préférentiellement la concentration est de 3 mM. [69] Preferably, the phytic acid used is a phytic acid powder in the form of sodium salt at a concentration preferably between 1 and 10 mM, preferably between 1 and 5 mM and more preferably the concentration is 3. mM.
[70] L’invention fonctionne particulièrement bien pour une concentration d’acide phytique comprise entre 2 et 3 comme décrit dans le tableau 1 ci-dessous. On observe ainsi que pour seulement 2,25 mM d’acide phytique on obtient les mêmes résultats qu’avec l’EDTA à 10 mM en termes de concentration de petits
ARN, ainsi qu’un rendement global d’extraction similaire. Une concentration de 3 mM permet un rendement d’extraction optimum des ARN de petits poids moléculaires. La concentration de 3 mM est également optimale pour avoir un meilleur rendement des autres composés d’intérêt comme les sucres, les composés phénoliques et les acides organiques. Avec une concentration d’acide phytique de 4,5 mM le rendement d’extraction des ARN de petits poids moléculaires est encore plus élevé, mais le rendement d’extraction global baisse. [70] The invention works particularly well for a phytic acid concentration between 2 and 3 as described in Table 1 below. It is thus observed that for only 2.25 mM of phytic acid the same results are obtained as with EDTA at 10 mM in terms of concentration of small RNA, as well as a similar overall extraction yield. A concentration of 3 mM allows an optimum extraction yield of RNAs of small molecular weights. The concentration of 3 mM is also optimal for having a better yield of other compounds of interest such as sugars, phenolic compounds and organic acids. With a phytic acid concentration of 4.5 mM the extraction yield of RNAs of small molecular weight is even higher, but the overall extraction yield decreases.
[71] [Tableau 1]
[71] [Table 1]
Tableau 1 : Rendement en ARN de petits poids moléculaire et rendement d’extraction global en fonction de la concentration en acide phytique Table 1: Small molecular weight RNA yield and overall extraction yield as a function of phytic acid concentration
[72] L’étape b) de traitement par l’acide phytique dure préférentiellement au moins 1 h, à une température comprise entre 20 et 80°C. Pendant cette étape, le mélange obtenu en a) est avantageusement mis sous agitation. [72] Stage b) of treatment with phytic acid preferably lasts at least 1 hour, at a temperature between 20 and 80 ° C. During this step, the mixture obtained in a) is advantageously stirred.
[73] De manière avantageuse, il est possible à la fin de l’étape b) d’ajouter des terres de diatomée afin de faciliter ultérieurement la séparation entre la matière végétale résiduelle solide et l’extrait (fraction soluble) à l’étape suivante. [73] Advantageously, it is possible at the end of step b) to add diatomaceous earth in order to subsequently facilitate the separation between the solid residual plant material and the extract (soluble fraction) in step next.
[74] Dans une étape c), on ajuste ensuite le pH du mélange obtenu en b) à une valeur comprise entre 6 et 8. [74] In a step c), the pH of the mixture obtained in b) is then adjusted to a value between 6 and 8.
[75] Le pH peut être ajusté par ajout d’une solution d’acide chlorhydrique (HCl) ou tout autre acide équivalent, compatible avec une utilisation cosmétique. L’acidification provoque la renaturation brutale de l’ADN (ré-appariement des brins de la double hélice). Toutefois l’ADN chromosomique, très long, ne parvient
pas à se réapparier complètement et forme des enchevêtrements insolubles. Au contraire, les petits ARN restent en solution. L’ADN et les petits ARN sont ainsi séparés en deux phases distinctes ; une phase solide contenant entre autres l’ADN chromosomique, et une phase liquide contenant, entre autres, les petits ARN. L’étape d’ajustement du pH à l’étape d) du procédé selon l’invention est une étape indispensable à l’extraction optimale des ARN de petit poids moléculaire, ainsi que autres phytomolécules d’intérêt ; à savoir les sucres, les composés phénoliques et les acides organiques. [75] The pH can be adjusted by adding a solution of hydrochloric acid (HCl) or any other equivalent acid, compatible with cosmetic use. Acidification causes the sudden renaturation of DNA (re-pairing of the double helix strands). However, the chromosomal DNA, which is very long, does not not to re-pair completely and form insoluble tangles. On the contrary, the small RNAs remain in solution. DNA and small RNAs are thus separated into two distinct phases; a solid phase containing, among other things, chromosomal DNA, and a liquid phase containing, among other things, small RNAs. The pH adjustment step in step d) of the process according to the invention is an essential step for the optimum extraction of low molecular weight RNAs, as well as other phytomolecules of interest; namely sugars, phenolic compounds and organic acids.
[76] Dans une étape d) on purifie le mélange obtenu en c) de manière à éliminer les parties aériennes de lavande solide résiduelle et récupérer la partie soluble qui constitue l’extrait brut aqueux selon l’invention. Toute méthode connue par l’homme du métier pourra être utilisée. Par exemple, le mélange obtenu en c) peut être filtré sur des filtres de porosité supérieure à 30 pm de façon à récolter le filtrât. Préférentiellement le mélange obtenu en c) est centrifugé à faible vitesse, par exemple pendant au moins 10 min à 4000 g, de manière à sédimenter la matière végétale résiduelle dans le culot et récupérer l’extrait brut aqueux dans le surnageant. [76] In step d), the mixture obtained in c) is purified so as to remove the aerial parts of residual solid lavender and to recover the soluble part which constitutes the crude aqueous extract according to the invention. Any method known to those skilled in the art can be used. For example, the mixture obtained in c) can be filtered through filters with a porosity greater than 30 μm so as to collect the filtrate. Preferably, the mixture obtained in c) is centrifuged at low speed, for example for at least 10 min at 4000 g, so as to sediment the residual plant material in the pellet and recover the crude aqueous extract in the supernatant.
[77] Dans une étape e) on contrôle le pH et on le réajuste à une valeur comprise entre 6 et 8. Préférentiellement le pH est réajusté à une valeur comprise entre 6 et 6,5, encore plus préférentiellement à une valeur de 6,5. Le pH est réajusté par l’ajout d’une solution d’acide chlorhydrique (HCl) ou encore n’importe quel acide équivalent compatible avec une utilisation cosmétique. [77] In a step e) the pH is checked and it is readjusted to a value between 6 and 8. Preferably the pH is readjusted to a value between 6 and 6.5, even more preferably to a value of 6, 5. The pH is readjusted by adding a solution of hydrochloric acid (HCl) or any equivalent acid compatible with cosmetic use.
[78] En effet, un pH inférieur à 6 peut entraîner la précipitation des acides nucléiques en général, donc celle des ARN de petit poids moléculaire d’une longueur d’au maximum 150 nucléotides. L’étape d’ajustement du pH à l’étape e) du procédé selon l’invention est une étape indispensable pour avoir une stabilité optimale des ARN de petit poids moléculaire dans l’extrait. [78] Indeed, a pH below 6 can lead to the precipitation of nucleic acids in general, and therefore that of small molecular weight RNAs of a maximum length of 150 nucleotides. The step of adjusting the pH in step e) of the process according to the invention is an essential step in order to have optimum stability of the low molecular weight RNAs in the extract.
[79] A la fin de l’étape e) on obtient un extrait brut concentré. [79] At the end of step e), a concentrated crude extract is obtained.
[80] Avantageusement le réajustement du pH de l’étape e) est précédé par au moins une filtration de l’extrait brut aqueux obtenu en d). Préférentiellement des
filtrations successives seront réalisées en abaissant le seuil de filtration de 20 à 50 mih jusqu’à une filtration stérilisante de 0,1 - 0,3 mih. [80] Advantageously, the readjustment of the pH of step e) is preceded by at least one filtration of the crude aqueous extract obtained in d). Preferably Successive filtrations will be carried out by lowering the filtration threshold from 20 to 50 mih until a sterilizing filtration of 0.1 - 0.3 mih.
[81] L’extrait obtenu à l’étape e) peut ensuite être dilué dans un solvant physiologiquement acceptable pour un usage cosmétique, de telle sorte que le poids sec soit compris entre 4 et 20 g/kg d’extrait sec par rapport au poids total de l’extrait dilué. Cette étape améliore la stabilité de l’extrait dans le temps. [81] The extract obtained in step e) can then be diluted in a physiologically acceptable solvent for cosmetic use, so that the dry weight is between 4 and 20 g / kg of dry extract relative to total weight of the diluted extract. This step improves the stability of the extract over time.
[82] L’invention a pour deuxième objet un extrait aqueux de parties aériennes de lavande enrichi en petits ARN d’une longueur d’au maximum 150 nucléotides, en sucres, en composés phénoliques, en acides organiques et dépourvu d’ADN, susceptible d’être obtenu par le procédé décrit ci-dessus. Cet extrait ne contient pas d’ADN (acide désoxyribonucléique). [82] The second subject of the invention is an aqueous extract of aerial parts of lavender enriched with small RNAs of a maximum length of 150 nucleotides, in sugars, in phenolic compounds, in organic acids and devoid of DNA, capable of to be obtained by the process described above. This extract does not contain DNA (deoxyribonucleic acid).
[83] L’invention a encore pour objet un extrait aqueux de parties aériennes de lavande enrichi en petits ARN d’une longueur d’au maximum 150 nucléotides, en sucres, en composés phénoliques et en acides organiques, directement obtenu par le procédé décrit ci-dessus. Cet extrait ne contient pas d’ADN (acide désoxyribonucléique). [83] A subject of the invention is also an aqueous extract of aerial parts of lavender enriched with small RNAs of a maximum length of 150 nucleotides, in sugars, in phenolic compounds and in organic acids, directly obtained by the method described. above. This extract does not contain DNA (deoxyribonucleic acid).
[84] En utilisant le procédé de l’invention selon les étapes a) à e) on obtient un extrait brut concentré aqueux de lavande de couleur ambre à ambre foncé ayant un poids sec de 10 à 30 g/kg, contenant 2 à 10 g/kg de sucres, 100 à 1500 mg/kg d’acides organiques, 500 à 2000 mg/kg de composés phénoliques et 40 à 200 mg/kg d’ARN de petit poids moléculaire d’une longueur d’au maximum 150 nucléotides. Néanmoins, pour des parties aériennes, en particulier la fleur de lavande de l’espèce Lavandula angustifolia , les extraits obtenus peuvent présenter une variabilité importante en fonction de facteurs tels que le lieu ou l’année de récolte, la saison, les conditions climatiques, le stress biotique, etc. [84] By using the process of the invention according to steps a) to e), an aqueous concentrated crude extract of amber to dark amber lavender is obtained having a dry weight of 10 to 30 g / kg, containing 2 to 10 g / kg of sugars, 100 to 1500 mg / kg of organic acids, 500 to 2000 mg / kg of phenolic compounds and 40 to 200 mg / kg of low molecular weight RNA with a maximum length of 150 nucleotides . However, for aerial parts, in particular the lavender flower of the Lavandula angustifolia species, the extracts obtained can exhibit significant variability depending on factors such as the place or year of harvest, the season, the climatic conditions, biotic stress, etc.
[85] L’extrait ainsi obtenu peut ensuite être dilué dans un solvant physiologiquement acceptable pour un usage cosmétique, de telle sorte que la concentration de l’extrait est alors ajustée à un poids sec compris entre 4 et 20 g/kg d’extrait sec par rapport au poids total de l’extrait dilué. [85] The extract thus obtained can then be diluted in a physiologically acceptable solvent for cosmetic use, so that the concentration of the extract is then adjusted to a dry weight of between 4 and 20 g / kg of extract. dry relative to the total weight of the diluted extract.
[86] A titre d’exemples illustratifs et non limitatifs de solvants physiologiquement acceptables, on peut citer l’eau, le glycérol, l’éthanol, le propanediol ainsi que sa
version naturelle appelée Zemea® issue du maïs, le butylène glycol, le dipropylène glycol, les diglycols éthoxylés ou propoxylés, les polyols cycliques ou tout mélange de ces solvants. [86] By way of illustrative and nonlimiting examples of physiologically acceptable solvents, mention may be made of water, glycerol, ethanol, propanediol as well as its natural version called Zemea® from corn, butylene glycol, dipropylene glycol, ethoxylated or propoxylated diglycols, cyclic polyols or any mixture of these solvents.
Ainsi l’extrait obtenu peut être dilué pour obtenir une concentration finale de 50 % de butylène glycol dérivé de plante, ou 50 % de propanediol dérivé de plante ou encore 30 % de glycérine dérivée de plante. Thus the extract obtained can be diluted to obtain a final concentration of 50% of butylene glycol derived from plants, or 50% of propanediol derived from plants or even 30% of glycerin derived from plants.
[87] Préférentiellement, l’extrait obtenu par le procédé selon l’invention est dilué dans du butylène glycol de telle sorte que l’extrait dilué comprenne une concentration finale en butylène glycol de 50 %. [87] Preferably, the extract obtained by the process according to the invention is diluted in butylene glycol so that the diluted extract comprises a final butylene glycol concentration of 50%.
[88] Cet extrait dit dilué comprend en poids du poids total de l’extrait de 4 à 20 g/kg d’extrait sec, 0,5 à 10 g/kg de sucres, 50 à 700 mg/kg d’acides organiques, 50 à 1500 mg/kg de composés phénoliques et 10 à 100 mg/kg d’ARN de petit poids moléculaire d’une longueur d’au maximum 150 nucléotides. [88] This so-called diluted extract comprises by weight of the total weight of the extract from 4 to 20 g / kg of dry extract, 0.5 to 10 g / kg of sugars, 50 to 700 mg / kg of organic acids , 50 to 1500 mg / kg of phenolic compounds and 10 to 100 mg / kg of low molecular weight RNA with a maximum length of 150 nucleotides.
[89] A titre d’exemple non limitatif, on peut citer un extrait dilué de Lavandula angustifolia contenant plus particulièrement des sucres à une concentration de 1 ,7 g/kg, des acides organiques à un teneur de 570 mg/kg, 620 mg/kg de composés phénoliques et 45 mg/kg d’ARN de petits poids moléculaires d’une longueur d’au maximum 150 nucléotides. [89] By way of nonlimiting example, mention may be made of a diluted extract of Lavandula angustifolia more particularly containing sugars at a concentration of 1.7 g / kg, organic acids at a content of 570 mg / kg, 620 mg. / kg of phenolic compounds and 45 mg / kg of low molecular weight RNA with a maximum length of 150 nucleotides.
[90] Au contraire, l’eau florale et l’huile essentielle de lavande contiennent principalement des molécules odorantes de nature terpénique et ne contiennent pas d’ARN de petits poids moléculaires d’une longueur d’au maximum 150 nucléotides, ni de sucres, ni de composés phénoliques ou d’acides organiques. [90] On the contrary, floral water and lavender essential oil mainly contain odorous molecules of terpene nature and do not contain RNA of small molecular weights of a maximum length of 150 nucleotides, nor of sugars. , nor of phenolic compounds or organic acids.
[91] L’extrait de l’invention comprend ainsi une large gamme de phytomolécules pouvant présenter des effets bénéfiques sur la peau, sans présenter de risque d’irritation cutanée ou autre dommage pour la santé. [91] The extract of the invention thus comprises a wide range of phytomolecules which may have beneficial effects on the skin, without presenting a risk of skin irritation or other damage to health.
[92] Par exemple les sucres participent activement à l’hydratation des couches épidermiques, et ce faisant à la résistance aux agressions extérieures, sans présenter aucun effet indésirable. L’extrait de lavande de l’invention contient plus particulièrement des mono- et des polysaccharides, qui ne sont présents ni dans l’eau florale ni dans l’huile essentielle de lavande.
[93] La lavande vraie fait partie de la famille des Lamiaceae qui possède un métabolisme particulier dit CAM pour Crassulacean Acid Metabolism. La plante stocke les acides organiques et plus particulièrement l’acide malique, l’acide citrique et l’acide tartrique à l'intérieur de ses cellules. Le procédé décrit dans l’invention permet d’extraire ces acides organiques ou AHA. Appliqués sur la peau ces AHA diminuent la cohésion cellulaire entre les cornéocytes, provoquent la desquamation des couches cornées et stimulent ainsi le renouvellement cellulaire. [92] For example, sugars actively participate in the hydration of the epidermal layers, and in doing so in resistance to external aggressions, without exhibiting any undesirable effects. The lavender extract of the invention more particularly contains mono- and polysaccharides, which are present neither in floral water nor in essential oil of lavender. [93] True lavender is part of the Lamiaceae family which has a particular metabolism known as CAM for Crassulacean Acid Metabolism. The plant stores organic acids and more particularly malic acid, citric acid and tartaric acid inside its cells. The process described in the invention makes it possible to extract these organic acids or AHAs. Applied to the skin, these AHAs reduce cell cohesion between the corneocytes, cause the desquamation of the horny layers and thus stimulate cell renewal.
[94] L'extrait de lavande selon l'invention est également enrichi en composés phénoliques, tels que les acides phénoliques. Ces molécules hydrosolubles connues pour leur activité antioxydante contribuent au potentiel antioxydant et protecteur de l'extrait de lavande de l'invention. [94] The lavender extract according to the invention is also enriched in phenolic compounds, such as phenolic acids. These water-soluble molecules known for their antioxidant activity contribute to the antioxidant and protective potential of the lavender extract of the invention.
[95] Un troisième aspect de l’invention est une composition cosmétique comprenant une quantité efficace d’un extrait aqueux enrichi en petits ARN d’une longueur d’au maximum 150 nucléotides, en sucres, en composés phénoliques et en acides organiques obtenu selon l’invention, en tant qu’ingrédient actif, et un milieu physiologiquement acceptable. [95] A third aspect of the invention is a cosmetic composition comprising an effective amount of an aqueous extract enriched in small RNA with a length of at most 150 nucleotides, in sugars, in phenolic compounds and in organic acids obtained according to the invention, as an active ingredient, and a physiologically acceptable medium.
L’extrait aqueux enrichi en petits ARN d’une longueur d’au maximum 150 nucléotides, en sucres, en composés phénoliques et en acides organiques, obtenu selon l’invention est avantageusement utilisé pour la préparation de compositions cosmétiques, à titre d’ingrédient actif. The aqueous extract enriched in small RNA with a length of at most 150 nucleotides, in sugars, in phenolic compounds and in organic acids, obtained according to the invention is advantageously used for the preparation of cosmetic compositions, as an ingredient. active.
[96] Avantageusement, l'extrait de parties aériennes de lavande selon l’invention est ajouté dans la composition à une concentration de 0,05 à 5 % en poids par rapport au poids total de la composition, préférentiellement à une concentration de 0,1 à 2,5 % en poids par rapport au poids total de la composition et encore plus préférentiellement à une concentration de 0,1 à 1 ,0 % en poids par rapport au poids total de la composition. [96] Advantageously, the extract of aerial parts of lavender according to the invention is added to the composition at a concentration of 0.05 to 5% by weight relative to the total weight of the composition, preferably at a concentration of 0, 1 to 2.5% by weight relative to the total weight of the composition and even more preferably at a concentration of 0.1 to 1.0% by weight relative to the total weight of the composition.
La composition utilisable selon l'invention pourra être appliquée par toute voie appropriée, notamment orale, ou topique externe, et la formulation des compositions sera adaptée par l'homme du métier. The composition which can be used according to the invention may be applied by any suitable route, in particular oral, or external topical, and the formulation of the compositions will be adapted by those skilled in the art.
[97] Préférentiellement, les compositions selon l'invention se présentent sous une forme adaptée à l’application par voie topique. Ces compositions doivent donc
contenir un milieu physiologiquement acceptable, c’est-à-dire compatible avec la peau et les phanères, sans risque d’inconfort lors de leur application et couvrent toutes les formes cosmétiques adaptées. [97] Preferably, the compositions according to the invention are provided in a form suitable for topical application. These compositions must therefore contain a physiologically acceptable medium, that is to say compatible with the skin and integuments, without risk of discomfort during their application and cover all suitable cosmetic forms.
[98] Les compositions pour la mise en œuvre de l’invention pourront notamment se présenter sous forme d'une solution aqueuse, hydroalcoolique ou huileuse, d'une émulsion huile-dans-eau, eau-dans-huile ou émulsions multiples ; elles peuvent aussi se présenter sous forme de suspensions, ou encore poudres, adaptées à une application sur la peau, les muqueuses, les lèvres et/ou les cheveux. [98] The compositions for implementing the invention may in particular be in the form of an aqueous, hydroalcoholic or oily solution, an oil-in-water, water-in-oil or multiple emulsions; they can also be in the form of suspensions, or even powders, suitable for application to the skin, mucous membranes, lips and / or hair.
[99] Ces compositions peuvent être plus ou moins fluides et avoir également l’aspect d’une crème, d’une lotion, d’un lait, d’un sérum, d’une pommade, d’un gel, d’une pâte ou d’une mousse. Elles peuvent aussi se présenter sous forme solide, comme un stick ou être appliquées sur la peau sous forme d’aérosol.[99] These compositions can be more or less fluid and also have the appearance of a cream, a lotion, a milk, a serum, an ointment, a gel, a paste or mousse. They can also be in solid form, such as a stick or be applied to the skin in the form of an aerosol.
A titre de milieu physiologiquement acceptable communément utilisé dans le domaine d'application envisagé, on peut citer par exemple des adjuvants nécessaires à la formulation, tels que des solvants, des épaississants, des diluants, des antioxydants, des colorants, des filtres solaires, des agents auto bronzants, des pigments, des charges, des conservateurs, des parfums, des absorbeurs d’odeur, des huiles essentielles, des vitamines, des acides gras essentiels, des tensioactifs, des polymères filmogènes, etc. As physiologically acceptable medium commonly used in the field of application envisaged, there may be mentioned, for example, adjuvants necessary for the formulation, such as solvents, thickeners, diluents, antioxidants, dyes, sunscreens, agents. self-tanning agents, pigments, fillers, preservatives, perfumes, odor absorbers, essential oils, vitamins, essential fatty acids, surfactants, film-forming polymers, etc.
[100] Dans tous les cas, l'homme de métier veillera à ce que ces adjuvants ainsi que leurs proportions soient choisis de telle manière à ne pas nuire aux propriétés avantageuses recherchées de la composition selon l’invention. Ces adjuvants peuvent, par exemple, correspondre à 0,01 à 20 % du poids total de la composition. Lorsque la composition selon l’invention est une émulsion, la phase grasse peut représenter de 5 à 80 % en poids et de préférence de 5 à 50 % en poids par rapport au poids total de la composition. Les émulsionnants et co émulsionnants utilisés dans la composition sont choisis parmi ceux classiquement utilisés dans le domaine considéré. Par exemple, ils peuvent être utilisés en une proportion allant de 0,3 à 30 % en poids par rapport au poids total de la composition.
[101] Selon un autre mode de réalisation avantageux de l’invention, l’extrait aqueux de lavande de l’invention peut être encapsulé ou inclus dans un vecteur cosmétique tels que les liposomes ou toute autre nano capsule ou microcapsule utilisée dans le domaine de la cosmétique ou adsorbé sur des polymères organiques poudreux, des supports minéraux comme les talcs et bentonites. [100] In all cases, a person skilled in the art will ensure that these adjuvants as well as their proportions are chosen so as not to harm the desired advantageous properties of the composition according to the invention. These adjuvants can, for example, correspond to 0.01 to 20% of the total weight of the composition. When the composition according to the invention is an emulsion, the fatty phase can represent from 5 to 80% by weight and preferably from 5 to 50% by weight relative to the total weight of the composition. The emulsifiers and co-emulsifiers used in the composition are chosen from those conventionally used in the field under consideration. For example, they can be used in a proportion ranging from 0.3 to 30% by weight relative to the total weight of the composition. [101] According to another advantageous embodiment of the invention, the aqueous lavender extract of the invention can be encapsulated or included in a cosmetic vector such as liposomes or any other nanocapsule or microcapsule used in the field of cosmetics or adsorbed on powdery organic polymers, mineral supports such as talcs and bentonites.
[102] Avantageusement, la composition selon l’invention peut comprendre, outre l’ingrédient actif selon l'invention, au moins un autre agent actif présentant des effets cosmétiques similaires et/ou complémentaires à ceux de l'invention. [102] Advantageously, the composition according to the invention can comprise, in addition to the active ingredient according to the invention, at least one other active agent exhibiting cosmetic effects similar and / or complementary to those of the invention.
[103] Par exemple, le ou les agents actifs additionnels peuvent être choisis parmi : les agents anti-âge, raffermissants, éclaircissants, hydratants, drainants, favorisant la microcirculation, exfoliants, desquamants, stimulant la matrice extracellulaire, activant le métabolisme énergétique, antibactériens, antifongiques, apaisants, anti-radicalaires, anti-UV, anti-acné, anti inflammatoires, anesthésiques, procurant une sensation de chaleur, procurant une sensation de fraîcheur, amincissants. [103] For example, the additional active agent (s) can be chosen from: anti-aging, firming, brightening, moisturizing, draining agents, promoting microcirculation, exfoliating, desquamating, stimulating the extracellular matrix, activating energy metabolism, antibacterial agents , antifungal, soothing, anti-radical, anti-UV, anti-acne, anti-inflammatory, anesthetics, providing a feeling of heat, providing a feeling of freshness, slimming.
[104] De tels agents actifs additionnels peuvent être choisis dans les groupes comprenant : [104] Such additional active agents can be chosen from the groups comprising:
- la vitamine A et notamment l'acide rétinoïque, le rétinol, le rétinol propionate, le rétinol palmitate ; - vitamin A and in particular retinoic acid, retinol, retinol propionate, retinol palmitate;
- la vitamine B3 et plus particulièrement le niacinamide, le nicotinate de tocophérol ; - vitamin B3 and more particularly niacinamide, tocopherol nicotinate;
- la vitamine B5, la vitamine B6, la vitamine B12, le panthénol ; - vitamin B5, vitamin B6, vitamin B12, panthenol;
- la vitamine C, notamment l'acide ascorbique, l'ascorbyl glucoside, l'ascorbyl tétrapalmitate, magnésium et sodium ascorbyl phosphate ; - vitamin C, in particular ascorbic acid, ascorbyl glucoside, ascorbyl tetrapalmitate, magnesium and sodium ascorbyl phosphate;
- les vitamines E, F, H, K, PP, le coenzyme Q10 ; - vitamins E, F, H, K, PP, coenzyme Q10;
- les inhibiteurs de métalloprotéinase, ou un activateur des Tl MP ; - metalloproteinase inhibitors, or an activator of Tl MP;
- la DHEA, ses précurseurs et dérivés ; - DHEA, its precursors and derivatives;
- les acides aminés tels que l'arginine, ornithine, hydroxyproline, hydroxyproline dipalmitate, palmitoylglycine, hydroxylysine, méthionine et ses dérivés, composés acides aminés N-acylés ; - Amino acids such as arginine, ornithine, hydroxyproline, hydroxyproline dipalmitate, palmitoylglycine, hydroxylysine, methionine and its derivatives, N-acylated amino acid compounds;
- les peptides naturels ou de synthèse, incluant les di-, tri-, tetra-, penta- et hexapeptides et leurs dérivés lipophiles, isomères et complexés avec d'autres
espèces telles qu'un ion métal (par exemple cuivre, zinc, manganèse, magnésium, et autres). A titre d’exemples, on peut citer les peptides commercialement connus sous les noms de MATRIXYL®, ARGIRELINE®, CHRONOGEN™, LAMINIXYL IS™, PEPTIDE Q10™, COLLAXYL ™ (brevet FR2827170, ASHLAND®), PEPTIDE VINCI 01 ™ (brevet FR2837098, ASHLAND®), PEPTIDE VINCI 02™ (brevet FR2841781 , ASHLAND®), ATPeptide™ (brevet FR2846883, ASHLAND®) ou encore le peptide de synthèse de séquence Arg-Gly-Ser-NH2, commercialisé sous le nom ATPeptide™ par ASHLAND® ; - natural or synthetic peptides, including di-, tri-, tetra-, penta- and hexapeptides and their lipophilic derivatives, isomers and complexed with others species such as a metal ion (eg copper, zinc, manganese, magnesium, and the like). As examples, mention may be made of the peptides commercially known under the names of MATRIXYL®, ARGIRELINE®, CHRONOGEN ™, LAMINIXYL IS ™, PEPTIDE Q10 ™, COLLAXYL ™ (patent FR2827170, ASHLAND®), PEPTIDE VINCI 01 ™ (patent FR2837098, ASHLAND®), PEPTIDE VINCI 02 ™ (patent FR2841781, ASHLAND®), ATPeptide ™ (patent FR2846883, ASHLAND®) or the synthetic peptide of sequence Arg-Gly-Ser-NH2, marketed under the name ATPeptide ™ by ASHLAND®;
- l’extrait d ’Artémia satina, commercialisé sous le nom GP4G™ (FR2817748, ASHLAND®) ; - the extract of Artemia satina, marketed under the name GP4G ™ (FR2817748, ASHLAND®);
- les extraits peptidiques végétaux tels que les extraits de lin (Lipigénine™, brevet FR2956818, ASHLAND®), les extraits de soja, d’épeautre, de vigne, de colza, de lin, de riz, de maïs, de pois ; - plant peptide extracts such as extracts of flax (Lipigénine ™, patent FR2956818, ASHLAND®), extracts of soybean, spelled, vine, rapeseed, flax, rice, corn, peas;
- les extraits de levures, par exemple le Dynagen™, (brevet FR2951946, ASHLAND®) ou l’Actopontine™ (brevet FR2944526, ASHLAND®) ; - yeast extracts, for example Dynagen ™ (patent FR2951946, ASHLAND®) or Actopontine ™ (patent FR2944526, ASHLAND®);
- l’acide déhydroacétique (DHA) ; - dehydroacetic acid (DHA);
- les phystostérols d'origine synthétique ou naturelle ; - phystosterols of synthetic or natural origin;
- l’acide salicylique et ses dérivés, les alpha- et bêta-hydroxyacides, les silanols ;- salicylic acid and its derivatives, alpha- and beta-hydroxy acids, silanols;
- les sucres aminés, glucosamine, D-glucosamine, N-acetyl glucosamine, N- acetyl-D-glucosamine, mannosamine, N-acetyl mannosamine, galactosamine, N- acetyl galactosamine ; - amino sugars, glucosamine, D-glucosamine, N-acetyl glucosamine, N-acetyl-D-glucosamine, mannosamine, N-acetyl mannosamine, galactosamine, N-acetyl galactosamine;
- les extraits de polyphénols, isoflavones, flavonoïdes, tels que les extraits de raisin, les extraits de pin, les extraits d'olive ; - extracts of polyphenols, isoflavones, flavonoids, such as grape extracts, pine extracts, olive extracts;
- les lipides tels que les céramides ou les phospholipides, les huiles d'origine animale, telles que le squalène ou le squalane ; les huiles végétales, telles que l'huile d'amande douce, de coprah, de ricin, de jojoba, d'olive, de colza, d'arachide, de tournesol, de germes de blé, de germes de maïs, de soja, de coton, de luzerne, de pavot, de potiron, d'onagre, de millet, d'orge, de seigle, de carthame, de passiflore, de noisette, de palme, de noyau d'abricot, d'avocat, de calendula ; les huiles végétales éthoxylées, le beurre de karité ; - lipids such as ceramides or phospholipids, oils of animal origin, such as squalene or squalane; vegetable oils, such as sweet almond, copra, castor, jojoba, olive, rapeseed, peanut, sunflower, wheat germ, corn germ, soybean oil, cotton, alfalfa, poppy, pumpkin, evening primrose, millet, barley, rye, safflower, passionflower, hazelnut, palm, apricot kernel, avocado, calendula ; ethoxylated vegetable oils, shea butter;
- tous écrans UV et filtres solaires ; - all UV screens and sun filters;
- l'AMP cyclique et ses dérivés, les agents activateurs de l'enzyme adénylate
cyclase et les agents inhibiteurs de l'enzyme phosphodiestérase, l’extrait de Centella asiatica , l’asiaticoside et l'acide asiatique, les méthyls xanthines, la théine, la caféine et ses dérivés, la théophylline, la théobromine, la forskoline, l’esculine et l’esculoside, les inhibiteurs d’ACE, le peptide Val-Trp, l’inhibiteur du neuropeptide Y, l’enkephaline, l’extrait de Ginkgo biloba , l’extrait de dioscorea, la rutine, l’extrait de yerba mate, l’extrait de guarana, les oligosaccharides, les polysaccharides, la carnitine, l’extrait de lierre, l’extrait de fucus, l’extrait hydrolysé de Prunella vulgaris , l’extrait hydrolysé de Celosia cristata, l’extrait 6'Anogeissus leiocarpus , l’extrait de feuilles de Manihot utilissima , la palmitoylcarnitine, la carnosine, la taurine, l’extrait de sureau, les extraits d’algue tel que l’extrait de Palmaria Palmata. - cyclic AMP and its derivatives, activators of the adenylate enzyme cyclase and inhibitors of the enzyme phosphodiesterase, extract of Centella asiatica, asiaticoside and asiatic acid, methyl xanthines, theine, caffeine and its derivatives, theophylline, theobromine, forskolin, l esculin and esculoside, ACE inhibitors, Val-Trp peptide, neuropeptide Y inhibitor, enkephalin, Ginkgo biloba extract, dioscorea extract, rutin, extract of yerba mate, guarana extract, oligosaccharides, polysaccharides, carnitine, ivy extract, wrack extract, hydrolyzed extract of Prunella vulgaris, hydrolyzed extract of Celosia cristata, extract 6 'Anogeissus leiocarpus, extract of leaves of Manihot utilissima, palmitoylcarnitine, carnosine, taurine, elderberry extract, seaweed extracts such as extract of Palmaria Palmata.
[105] L’invention a pour quatrième objet l’utilisation cosmétique d’une composition comprenant l’extrait de lavande de l’invention pour le soin de la peau, du cuir chevelu et des phanères, plus particulièrement pour protéger la peau des agressions externes et de l’oxydation, lutter contre les signes du vieillissement cutané, augmenter la photoprotection, éclaircir la peau, améliorer l’hydratation de la peau, renforcer la fonction barrière, apaiser la peau, ou encore pour améliorer les mécanismes biologiques associés à la réparation de la peau pendant la nuit. [105] A fourth subject of the invention is the cosmetic use of a composition comprising the lavender extract of the invention for caring for the skin, scalp and integuments, more particularly for protecting the skin from attacks. externalities and oxidation, fight against the signs of skin aging, increase photoprotection, lighten the skin, improve skin hydration, strengthen the barrier function, soothe the skin, or to improve the biological mechanisms associated with overnight skin repair.
[106] La peau est un organe composé de plusieurs couches (derme, épiderme et stratum corneum ), qui recouvre toute la surface du corps et assure des fonctions protectrices vis-à-vis des agressions externes, sensitives, immunitaires, métaboliques, thermorégulatrices ou encore de barrière limitant la déshydratation. [106] The skin is an organ composed of several layers (dermis, epidermis and stratum corneum), which covers the entire surface of the body and provides protective functions against external, sensitive, immune, metabolic, thermoregulatory or still barrier limiting dehydration.
[107] En particulier, le stratum corneum assure un rôle de barrière physique protectrice, communément nommé « fonction barrière de la peau ». Cette fonction revêt une importance majeure dans l’homéostasie tissulaire et dans la protection vis-à-vis de l’environnement extérieur. [107] In particular, the stratum corneum acts as a protective physical barrier, commonly known as the “skin barrier function”. This function is of major importance in tissue homeostasis and in protection from the external environment.
[108] L'aspect de la peau peut être modifié par des altérations internes (vieillissement intrinsèque, maladies et changements hormonaux tels que la grossesse) ou externes (facteurs environnementaux, tels que la pollution, la lumière du soleil, les pathogènes, les variations de température, etc.). Toutes ces
altérations affectent non seulement la peau, mais aussi les annexes kératiniques telles que les poils, les cils, les sourcils, les ongles et les cheveux. [108] The appearance of the skin can be modified by internal alterations (intrinsic aging, diseases and hormonal changes such as pregnancy) or external (environmental factors, such as pollution, sunlight, pathogens, variations temperature, etc.). All of these alterations affect not only the skin, but also the keratinous appendages such as body hair, eyelashes, eyebrows, nails and hair.
[109] L’extrait de parties aériennes de lavande de l’invention a été testé sur les principaux marqueurs biologiques associés aux mécanismes de réparation de la peau pendant la nuit. Les mécanismes qui siègent dans la peau pendant la nuit incluent l’augmentation de la réparation de l’ADN, du taux de prolifération cellulaire, de la température cutanée, du flux sanguin cutané, de l’incidence des démangeaisons, ainsi que de la perméabilité de la barrière cutanée, conduisant à une perte d’hydratation (Matsui M.S. et al, Biological rhythms in the skin, Int. J. Mol. Soi. 2016, 17,801). L’extrait de parties aériennes de lavande de l’invention a été en particulier évalué sur le taux de réparation des dimères de pyrimidines (CPD pour Cyclobutane Pyrimidine Dimers). Le rythme jour/nuit perçu au niveau du système nerveux central, comprend la production de mélatonine par la glande pinéale (Slominski A.T. et al, Melatonin : A cutaneous perspective on its production, metabolism, and functions. J Invest Dermatol, 2018 March ; [109] The extract of the aerial parts of lavender of the invention has been tested on the main biomarkers associated with the mechanisms of repair of the skin during the night. Mechanisms that take place in the skin overnight include increased DNA repair, rate of cell proliferation, skin temperature, skin blood flow, incidence of itching, as well as permeability. of the skin barrier, leading to a loss of hydration (Matsui MS et al, Biological rhythms in the skin, Int. J. Mol. Soi. 2016, 17,801). The extract of aerial parts of lavender of the invention was in particular evaluated on the repair rate of pyrimidine dimers (CPD for Cyclobutane Pyrimidine Dimers). The day / night rhythm perceived at the level of the central nervous system, includes the production of melatonin by the pineal gland (Slominski A.T. et al, Melatonin: A cutaneous perspective on its production, metabolism, and functions. J Invest Dermatol, 2018 March;
138(3) :490-499). La mélatonine est également produite localement dans la peau à partir du tryptophane. Ces fonctions contribuent à diminuer le taux d’espèces réactives de l’oxygène et de l’azote (ROS et RNS, pour reactive oxygen species et reactive nitrogen species, respectivement). En effet, en plus de son rôle direct de piégeur de radicaux libres, la mélatonine stimule la production d’enzymes antioxydantes telles que la catalase et la superoxide dismutase et intervient dans la réparation de l’ADN. En optimisant le fonctionnement de la mitochondrie, la mélatonine contribue aussi à augmenter le taux d’ATP produit par la cellule. L’effet de l’extrait de parties aériennes de lavande de l’invention a été évalué sur le taux de mélatonine de la peau et sur l’expression de l’enzyme AANAT (Aralkylamine N-Acetyltransferase ou sérotonine N-acétyl transférase ou timezyme) qui catalyse la N-acétylation de la sérotonine en N-acetylserotonine, ultime étape de la synthèse de la mélatonine. De plus, l’application topique de mélatonine exogène a montré un effet sur la perte des cheveux associée à l’alopécie androgénétique (Fisher TW, Topical melatonin fortreatment of androgenetic alopecia, Int J Trichology, 2012 Oct-Dec, 4(4) :236-245).
[110] L’extrait de parties aériennes de lavande de l’invention a démontré son efficacité pour augmenter la production de mélatonine dans des biopsies de peau en culture. 138 (3): 490-499). Melatonin is also produced locally in the skin from tryptophan. These functions help to reduce the level of reactive oxygen and nitrogen species (ROS and RNS, for reactive oxygen species and reactive nitrogen species, respectively). In fact, in addition to its direct role as a free radical scavenger, melatonin stimulates the production of antioxidant enzymes such as catalase and superoxide dismutase and is involved in DNA repair. By optimizing the functioning of the mitochondria, melatonin also helps to increase the level of ATP produced by the cell. The effect of the extract of aerial parts of lavender of the invention was evaluated on the level of melatonin in the skin and on the expression of the enzyme AANAT (Aralkylamine N-Acetyltransferase or serotonin N-acetyl transferase or timezyme ) which catalyzes the N-acetylation of serotonin to N-acetylserotonin, the final step in the synthesis of melatonin. In addition, topical application of exogenous melatonin has shown an effect on hair loss associated with androgenetic alopecia (Fisher TW, Topical melatonin fortreatment of androgenetic alopecia, Int J Trichology, 2012 Oct-Dec, 4 (4): 236-245). [110] The extract of aerial parts of lavender of the invention has been shown to be effective in increasing the production of melatonin in cultured skin biopsies.
[111] Des altérations de la fonction barrière résultent d’agressions externes telles que les UV. Les conséquences sont majeures au niveau de la perte de la cohésion cellulaire et de l’intégrité mécanique. Certaines enzymes impliquées dans les phases terminales de la différenciation kératinocytaire jouent un rôle clé dans la protection face aux UV. Des modifications de l’expression et/ou de l’activité de ces enzymes ont des conséquences importantes sur l’intégrité de la fonction barrière et l’homéostasie de la peau. [111] Alterations in the barrier function result from external aggressions such as UV rays. The consequences are major in terms of the loss of cell cohesion and mechanical integrity. Certain enzymes involved in the terminal phases of keratinocyte differentiation play a key role in protection against UV rays. Changes in the expression and / or activity of these enzymes have important consequences for the integrity of the barrier function and homeostasis of the skin.
[112] L’extrait de parties aériennes de lavande de l’invention a démontré son efficacité pour renforcer la fonction barrière et ainsi améliorer la protection de la peau vis-à-vis des agressions extérieures (radiations UV, pollution, microorganismes, etc.). [112] The extract of aerial parts of lavender of the invention has demonstrated its effectiveness in reinforcing the barrier function and thus improving the protection of the skin against external aggressions (UV radiation, pollution, microorganisms, etc.). ).
[113] L’extrait de parties aériennes de lavande de l’invention a démontré son efficacité pour diminuer le taux de mélanine dans des biopsies de peau, et ainsi induire un effet éclaircissant. [113] The extract of the aerial parts of lavender of the invention has been shown to be effective in reducing the level of melanin in skin biopsies, and thus inducing a lightening effect.
Exemples Examples
[114] A titre illustratif, des exemples de mode de réalisation du procédé selon l’invention sont décrits ci-dessous. [114] By way of illustration, exemplary embodiments of the method according to the invention are described below.
[115] Exemple 1 : Préparation d’un extrait de lavande ( Lavandula angustifolia) de la famille des Lamiaceae, enrichi en petits ARN [115] Example 1: Preparation of an extract of lavender (Lavandula angustifolia) of the Lamiaceae family, enriched in small RNA
Procédé d’extraction Extraction process
[116] Les fleurs de lavande de l’espèce Lavandula angustifolia sont préalablement séchées dans un endroit ventilé, à l’abri de la lumière. Dans une première étape,[116] The lavender flowers of the Lavandula angustifolia species are first dried in a ventilated place, protected from light. In a first step,
3 % de fleurs séchées de lavande et de tiges portant les fleurs sont broyées sous forme de poudre à une granulométrie allant de 500 pm à 1 mm préférentiellement à 800 pm, soit l’équivalent de 30 g de poudre de fleurs de lavande séchées dans 968 g d’eau distillée. Puis on ajoute 2 g/L soit 3 mM d’acide phytique. Le pH est ajusté à 10,8 pour un enrichissement optimal de l’extrait en ARN de petits poids moléculaires.
[117] Le mélange est ensuite chauffé 1 h à 80°C sous agitation. 3% of dried lavender flowers and stems bearing the flowers are ground in the form of powder with a particle size ranging from 500 μm to 1 mm, preferably at 800 μm, i.e. the equivalent of 30 g of powder of dried lavender flowers in 968 g of distilled water. Then 2 g / L or 3 mM of phytic acid are added. The pH is adjusted to 10.8 for optimal enrichment of the extract in RNA of small molecular weights. [117] The mixture is then heated for 1 hour at 80 ° C. with stirring.
Après cette heure d’extraction, on ajoute à ce mélange des terres de diatomée afin de faciliter la séparation ultérieure entre la matière végétale résiduelle solide et l’extrait (fraction soluble). After this hour of extraction, diatomaceous earth is added to this mixture to facilitate subsequent separation between the residual solid plant material and the extract (soluble fraction).
[118] Le mélange est ensuite filtré à l’aide de filtres de porosité de 30 pm, pour ôter la matière solide. Le pH est ensuite ajusté à pH 7,5 à l’aide d’une solution d’HCI. Des filtrations séquentielles sur filtres de porosité décroissante sont alors réalisées afin de clarifier l’extrait végétal jusqu’à une filtration stérilisante à 0,2 pm. [118] The mixture is then filtered using 30 µm porosity filters to remove solid matter. The pH is then adjusted to pH 7.5 using an HCl solution. Sequential filtrations on filters of decreasing porosity are then carried out in order to clarify the plant extract to sterilizing filtration at 0.2 μm.
[119] A l’issue de cette étape, le pH est contrôlé, puis il est ajusté à 6,3 avec une solution d’HCI. 6 et 6,5 et préserver les petits ARN de l’extrait. [119] At the end of this step, the pH is checked, then it is adjusted to 6.3 with an HCl solution. 6 and 6.5 and preserve the small RNAs in the extract.
On obtient un extrait aqueux ayant un poids sec de 12,6 g/kg. An aqueous extract is obtained having a dry weight of 12.6 g / kg.
Caractérisation de l’extrait de lavande Characterization of lavender extract
[120] L’extrait obtenu à un poids sec de 12,6 g/kg. [120] The extract obtained at a dry weight of 12.6 g / kg.
L’analyse physico-chimique montre que l’extrait obtenu présente une concentration de 3,7 g/kg de sucres totaux, 1160 g/kg d’acides organiques totaux, 1270 mg/kg de composés phénoliques totaux et 118 mg/kg d’ARN de petits poids moléculaires d’une longueur d’au maximum 150 nucléotides. Physico-chemical analysis shows that the extract obtained has a concentration of 3.7 g / kg of total sugars, 1160 g / kg of total organic acids, 1270 mg / kg of total phenolic compounds and 118 mg / kg of RNA of small molecular weights of up to 150 nucleotides in length.
L’extrait est ensuite dilué avec un solvant cosmétique physiologiquement acceptable et permettant de garantir une meilleure stabilité et une meilleure conservation de l’extrait dans le temps. The extract is then diluted with a physiologically acceptable cosmetic solvent to guarantee better stability and better conservation of the extract over time.
[121] La dilution est réalisée avec du butylène glycol dérivé de plante de manière à obtenir une concentration finale de 50 % de butylène glycol et 50 % d’extrait de lavande. L’extrait ainsi dilué possède alors un poids sec de 6 g/kg, et présente une concentration de 1 ,7 g/kg de sucres totaux, 570 mg/kg d’acides organiques totaux, 620 mg/kg de composés phénoliques totaux et 45 mg/kg d’ARN de petits poids moléculaires d’une longueur d’au maximum 150 nucléotides. [121] The dilution is carried out with butylene glycol derived from plants so as to obtain a final concentration of 50% butylene glycol and 50% lavender extract. The extract thus diluted then has a dry weight of 6 g / kg, and has a concentration of 1.7 g / kg of total sugars, 570 mg / kg of total organic acids, 620 mg / kg of total phenolic compounds and 45 mg / kg of low molecular weight RNA with a maximum length of 150 nucleotides.
Méthodes de dosage utilisées pour déterminer la quantité des différents composés contenus dans l'extrait final de lavande : Assay methods used to determine the amount of the different compounds contained in the final lavender extract:
[122] La teneur totale en sucres de l'extrait a été déterminée par dosage spectrophotométrique issu d’une adaptation du dosage décrit par Dubois et al.
(1956) (Dubois et al., "Méthode colorimétrique pour la détermination des sucres et des substances apparentées", Anal. Chem., 1956, 28 (3), 350-356). Cette analyse consiste en la dissolution de la matière première dans l'acide sulfurique concentré puis en réagissant avec du phénol pour former un complexe coloré. L'absorbance du complexe est lue sur le spectrophotomètre à 490 nm. La teneur en sucre est déterminée à l'aide d'une courbe standard de glucose. Une analyse CCM a permis de mettre en évidence que les sucres majoritaires présents dans l’extrait de l’invention sont les molécules de glucose et fructose ainsi que des sucres de hauts poids moléculaires (oligo et polysaccharides). [122] The total sugar content of the extract was determined by spectrophotometric assay resulting from an adaptation of the assay described by Dubois et al. (1956) (Dubois et al., "Colorimetric method for the determination of sugars and related substances", Anal. Chem., 1956, 28 (3), 350-356). This analysis consists of dissolving the raw material in concentrated sulfuric acid and then reacting with phenol to form a colored complex. The absorbance of the complex is read on the spectrophotometer at 490 nm. The sugar content is determined using a standard glucose curve. A TLC analysis made it possible to demonstrate that the major sugars present in the extract of the invention are glucose and fructose molecules as well as sugars of high molecular weight (oligo and polysaccharides).
[123] La teneur totale en polyphénols de l'extrait de lavande a été déterminée par la méthode de dosage spectrophotométrique de Folin-Ciocalteu (Singleton et al., Analyse des phénols totaux et d'autres substrats d'oxydation et antioxydants au moyen du réactif Folin-Ciocalteu, 1999, 299: 152). Les composés de type polyphénols présents dans l'échantillon réagissent avec le réactif de Folin- Ciocalteu, l'oxydation du réactif donne une couleur bleue. L'absorbance de l'échantillon est lue sur le spectrophotomètre à 760 nm. Le contenu est exprimé en équivalents d'acide gallique à l'aide d'une courbe standard d'acide gallique. [123] The total polyphenol content of the lavender extract was determined by the Folin-Ciocalteu spectrophotometric assay method (Singleton et al., Analysis of total phenols and other oxidation substrates and antioxidants using the Folin-Ciocalteu reagent, 1999, 299: 152). The polyphenol-like compounds present in the sample react with the Folin-Ciocalteu reagent, oxidation of the reagent gives a blue color. The absorbance of the sample is read on the spectrophotometer at 760 nm. The content is expressed in gallic acid equivalents using a gallic acid standard curve.
[124] La caractérisation des acides organiques a été effectuée sur l’extrait de Lavande de l’exemple 1 , une eau florale et une huile essentielle de référence.[124] The characterization of organic acids was carried out on the Lavender extract of Example 1, a floral water and a reference essential oil.
Une analyse chromatographique liquide haute performance, couplée à un détecteur de masse a été utilisée. Tous les échantillons ont été séparés sur une colonne EC 150 / 4,6 Nucleoshell RP 18plus-5pm (150x4,6 mm) (Macherey Nagel: 763236.46) par un système HPLC Agilent 1260 (Agilent Technologies). Le débit était de 0,3 ml / min. La phase mobile consistait en une solution d'acide formique (HCOOH) à 0,01 % (A) et d'acétonitrile (B). Le programme de gradient a facilité l’élution tel que décrit dans le tableau 2. High performance liquid chromatographic analysis coupled with a mass detector was used. All samples were separated on an EC 150 / 4.6 Nucleoshell RP 18plus-5pm (150x4.6mm) column (Macherey Nagel: 763236.46) by an Agilent 1260 HPLC system (Agilent Technologies). The flow rate was 0.3 ml / min. The mobile phase consisted of a solution of formic acid (HCOOH) at 0.01% (A) and acetonitrile (B). The gradient program facilitated the elution as described in Table 2.
[125] [Tableau 2]
[125] [Table 2]
[126] La température de la colonne a été maintenue à 25°C et le volume d'injection était de 5 pL. La détection a été effectuée par un détecteur de spectromètre de masse ACQUITY Qda (WATERS) avec une source d’ions électrospray en mode négatif. La source a été réglée à une tension capillaire de 0,8 kV et à une température de sonde de 600°C. [126] The temperature of the column was maintained at 25 ° C and the injection volume was 5 µL. Detection was performed by an ACQUITY Qda (WATERS) mass spectrometer detector with an electrospray ion source in negative mode. The source was set to a capillary voltage of 0.8 kV and a probe temperature of 600 ° C.
M/z et la tension au cône ont été ciblés pour chaque composé tel que décrit dans le tableau 3. M / z and cone tension were targeted for each compound as described in Table 3.
[127] [Tableau 3]
[127] [Table 3]
[128] L’identification des acides organiques a été réalisée en comparant les temps de rétention et les pics spectraux de masse de l’échantillon avec un étalon. L'estimation quantitative des acides organiques a été réalisée sur la base de la
surface maximale des concentrations de l'échantillon comparée à la surface maximale des étalons. [128] The identification of organic acids was performed by comparing retention times and mass spectral peaks of the sample with a standard. The quantitative estimate of organic acids was carried out on the basis of the maximum area of the sample concentrations compared to the maximum area of the standards.
[129] L’analyse HPLC-MS qui permet de quantifier et d’identifier les acides organiques contenus dans l’extrait, montre que seul l’extrait de lavande contient différents types d’acides organiques, principalement acide citrique, malique et tartrique, tels que présentés sur la figure 1. L’analyse HPLC-MS montre que ces acides organiques ne sont présents ni dans l’eau florale de lavande vraie ni dans l’huile essentielle de lavande vraie. [129] The HPLC-MS analysis, which makes it possible to quantify and identify the organic acids contained in the extract, shows that only the lavender extract contains different types of organic acids, mainly citric, malic and tartaric acid, as presented in FIG. 1. HPLC-MS analysis shows that these organic acids are present neither in the floral water of true lavender nor in the essential oil of true lavender.
[130] La quantification des ARN de bas poids moléculaires a été réalisée par une technique d’électrophorèse miniaturisée sur des puces microfluidiques spécifiques de l'analyse des acides nucléiques telle que celle des ARN de petits poids moléculaires (Bioanalyseur 2100®, Agilent). Cette méthode permet de déterminer la taille et la concentration d’acides nucléiques contenues dans un extrait à partir de quelques microlitres. Le résultat se présente sous forme d’un graphique avec en ordonnée une unité arbitraire de fluorescence (FU) et en abscisse le nombre de nucléotides (nt). Un marqueur interne est ajouté à chaque analyse (pic à 25 nt sur la figure 2), et sert de contrôle interne pour valider le bon déroulement de l’analyse. [130] The quantification of low molecular weight RNAs was performed by a miniaturized electrophoresis technique on microfluidic chips specific for nucleic acid analysis such as that of low molecular weight RNAs (Bioanalyzer 2100®, Agilent). This method makes it possible to determine the size and concentration of nucleic acids contained in an extract from a few microliters. The result is presented as a graph with an arbitrary fluorescence unit (FU) on the ordinate and the number of nucleotides (nt) on the abscissa. An internal marker is added to each analysis (peak at 25 nt in Figure 2), and serves as an internal control to validate the proper conduct of the analysis.
[131] La figure 2 représente l’analyse des ARN de petits poids moléculaire par le Bioanalyseur 2100. A : extrait de lavande selon l’exemple 1. B : extrait conventionnel de lavande selon exemple 2. [131] Figure 2 shows the analysis of small molecular weight RNAs by the 2100 Bioanalyzer. A: lavender extract according to Example 1. B: conventional lavender extract according to Example 2.
[132] L’analyse par bioanalyseur montre que le procédé décrit dans la présente invention permet d’extraire les ARN de petits poids moléculaires de la lavande, tel qu’illustré sur la figure 2A. La figure 2A montre que les ARN présents dans l’extrait de lavande de l’invention ont des poids moléculaires répartis entre plus de 25 et environ 150 nucléotides. [132] Bioanalyzer analysis shows that the method described in the present invention extracts low molecular weight RNAs from lavender, as shown in Figure 2A. Figure 2A shows that the RNAs present in the lavender extract of the invention have molecular weights ranging from greater than 25 to about 150 nucleotides.
[133] Un procédé d’extraction conventionnelle telle que la macération décrit ci- dessous dans l’exemple 2 ne permet pas d’extraire les ARN de petits poids moléculaires (figure 2B). L’analyse a permis également de démontrer qu’il n’y a pas non plus ces molécules ni dans l’eau florale ni dans l’huile essentielle. De plus cette analyse permet de démontrer l’absence d’ADN dans l’extrait.
[134] L’analyse des composés volatiles odorants (VOC) a été effectuée sur l’extrait de Lavande selon l’invention, l’eau florale et l’huile essentielle par GC-FID. Tous les échantillons ont été séparés sur une colonne GC OPTIMA 5HT de 30 mx 250 pm x 0,25 pm (Macherey-Nagel 726106.30) par une chromatographie gazeuse Agilent GC / FID 7890A (Agilent Technologies). 3 pL de produits échantillons ont été injectés sur la colonne à un flux de 1 ,3 ml / min, en utilisant de l'hélium comme gaz vecteur sur un four programmé qui monte de 75°C à 320°C en 40 min. [133] A conventional extraction process such as the maceration described below in Example 2 does not make it possible to extract the RNAs of small molecular weights (FIG. 2B). The analysis also made it possible to demonstrate that there are no these molecules either in the floral water or in the essential oil. In addition, this analysis makes it possible to demonstrate the absence of DNA in the extract. [134] The analysis of volatile odorous compounds (VOC) was carried out on the extract of Lavender according to the invention, floral water and essential oil by GC-FID. All samples were separated on a 30 mx 250 µm x 0.25 µm OPTIMA 5HT GC column (Macherey-Nagel 726106.30) by Agilent GC / FID 7890A gas chromatography (Agilent Technologies). 3 µL of sample products were injected onto the column at a flow rate of 1.3 ml / min, using helium as carrier gas on a programmed oven which rises from 75 ° C to 320 ° C in 40 min.
[135] Les molécules ont été détectées sur un détecteur à ionisation de flamme à 230°C, en utilisant de l'hydrogène (30 ml / min) et de l'air (400 ml / min) pour la flamme. L’identification des VOC se fait par comparaison des temps de rétention des composés. [135] The molecules were detected on a flame ionization detector at 230 ° C, using hydrogen (30 ml / min) and air (400 ml / min) for the flame. The identification of VOCs is done by comparing the retention times of the compounds.
[136] Pour les échantillons aqueux une extraction liquide/liquide dans l’hexane (1 :1) est réalisée préalablement à l’injection. Du sulfate de magnésium est ajouté à la phase organique afin d’éliminer toute trace d’eau. [136] For aqueous samples, liquid / liquid extraction in hexane (1: 1) is performed prior to injection. Magnesium sulfate is added to the organic phase to remove all traces of water.
[137] [Tableau 4]
[137] [Table 4]
Tableau A : Détermination des composés volatils odorants dans l’extrait de lavandeTable A: Determination of volatile odorous compounds in lavender extract
[138] Les résultats de l’analyse par GC-FID du tableau 4 permettent de mettre en évidence que l’extrait de lavande de l’exemple 1 ne contient aucune molécule odorante, de nature terpénique, contrairement à l’eau florale et l’huile essentielle de lavande connues pour contenir majoritairement ces molécules. [138] The results of the GC-FID analysis of Table 4 make it possible to demonstrate that the lavender extract of Example 1 does not contain any odorous molecule, of terpene nature, unlike floral water and essential oil of lavender known to mainly contain these molecules.
[139] Exemple 2 préparation d’un macérat de lavande
[140] Afin de comparer une extraction dite classique à l’extrait de l’invention, un macérat de lavande a été réalisé, en engageant la même quantité de fleurs séchées de lavande de l’espèce Lavandula angustifolia que dans l’exemple 1 soit 3 % de fleurs de lavande séchées broyées mises dans de l’eau distillée. Le mélange est ensuite chauffé 1 h à 80°C, puis le mélange est filtré par une première filtration à large porosité de 30 pm afin d’ôter la matière végétale résiduelle solide de la partie liquide puis par filtration séquentielle de porosité décroissante jusqu’ à 0,2 pm. Ce procédé a pour but de préparer un extrait contrôle pour obtenir des données analytiques comparatives par rapport à l’extrait de lavande obtenu par le procédé de l’invention. Les résultats obtenus sont illustrés dans la figure 2B et dans le texte de la demande. [139] Example 2 preparation of a lavender macerate [140] In order to compare a so-called classic extraction with the extract of the invention, a lavender macerate was carried out, using the same quantity of dried lavender flowers of the species Lavandula angustifolia as in Example 1, either 3% crushed dried lavender flowers put in distilled water. The mixture is then heated for 1 h at 80 ° C, then the mixture is filtered by a first filtration with a large porosity of 30 μm in order to remove the solid residual plant material from the liquid part, then by sequential filtration of decreasing porosity until 0.2 µm. The purpose of this process is to prepare a control extract in order to obtain comparative analytical data with respect to the lavender extract obtained by the process of the invention. The results obtained are illustrated in FIG. 2B and in the text of the application.
[141] Exemple 3 : Evaluation de l’extrait de Lavandula angustifolia de l’exemple 1 sur les espèces oxygénées réactives après application d’un stress de lumière visible sur des kératinocytes humains normaux : [141] Example 3: Evaluation of the Lavandula angustifolia extract of Example 1 on reactive oxygen species after application of visible light stress on normal human keratinocytes:
[142] Principe : [142] Principle:
Le but de cette étude est de montrer l’effet de l’extrait de lavande préparé selon l’exemple 1 sur la diminution des espèces oxygénées réactives générées par un stress de lumière visible. Ce type de lumière entre 400 et 700 nm a pour but de mimer la lumière du jour. Les espèces oxygénées réactives sont impliquées dans différents mécanismes d’altération des protéines et de l’ADN, en lien avec le vieillissement cutané. The aim of this study is to show the effect of the lavender extract prepared according to Example 1 on the decrease in reactive oxygen species generated by visible light stress. This type of light between 400 and 700 nm is intended to mimic daylight. Reactive oxygen species are involved in different mechanisms of protein and DNA damage, linked to skin aging.
[143] Protocole : [143] Protocol:
Des kératinocytes humains normaux sont traités par l’extrait de l’exemple 1 pendant une nuit. Les cellules sont ensuite exposées à la lumière visible générée par un spot de 24 Watt et de 5000°Kelvin, permettant de mimer la lumière du jour. Cette exposition est répétée 4 fois pendant 10 minutes, au cours de la journée. Le traitement est de nouveau appliqué pendant la nuit, puis les cellules sont de nouveau soumises au même stress de lumière visible. A l’issue de ce stress, les espèces réactives de l’oxygène sont détectées par la sonde mitochondriale MitoSOX™ Red (ThermoFisher scientific). Normal human keratinocytes are treated with the extract of Example 1 overnight. The cells are then exposed to visible light generated by a spot of 24 Watt and 5000 ° Kelvin, making it possible to mimic daylight. This exposure is repeated 4 times for 10 minutes, during the day. The treatment is applied again overnight, then the cells are again subjected to the same visible light stress. After this stress, reactive oxygen species are detected by the mitochondrial probe MitoSOX ™ Red (ThermoFisher scientific).
[144] Résultats : [144] Results:
L’application du stress de lumière du jour a entraîné une augmentation des
espèces réactives de l’oxygène (EROs) de +43 % par rapport aux cellules non exposées. Lorsque les cellules ont été traitées par l’extrait de l’exemple 1 à 0,1 % (dilution volume/volume), les EROs sont diminuées de façon hautement significative de -12 % par rapport aux cellules non traitées. Un macérat de lavande obtenu selon l’exemple 2 est testé dans les mêmes conditions a permis une diminution plus faible de -5 %. The application of daylight stress resulted in an increase in reactive oxygen species (ROS) by + 43% compared to unexposed cells. When the cells were treated with the extract of Example 1 at 0.1% (volume / volume dilution), the ROS are highly significantly reduced by -12% compared to the untreated cells. A lavender macerate obtained according to Example 2 is tested under the same conditions, allowing a smaller decrease of -5%.
[145] Conclusion : [145] Conclusion:
L’extrait de lavande a montré une activité antioxydante, dirigée contre les espèces réactives de l’oxygène au niveau mitochondrial. Cette activité s’est révélée supérieure à celle obtenue avec un extrait de lavande issu d’une macération classique. Lavender extract has shown antioxidant activity, directed against reactive oxygen species at the mitochondrial level. This activity has been shown to be superior to that obtained with a lavender extract obtained from conventional maceration.
[146] Exemple 4 : Evaluation de l’extrait de l’exemple 1 sur les dommages de l’ADN dans des mélanocytes humains normaux exposés à un stress UVB : [146] Example 4: Evaluation of the extract from Example 1 on DNA damage in normal human melanocytes exposed to UVB stress:
[147] Principe : [147] Principle:
L’instabilité génomique peut être définie comme l’ensemble des modifications chimiques de l’ADN, intervenant lors de différents processus et pouvant s’accumuler au cours du temps. Les altérations de l’ADN représentent une composante majeure du photo-vieillissement. Dans la présente étude, nous nous sommes intéressés aux dommages créés par les UVB dans les mélanocytes.Genomic instability can be defined as all the chemical changes in DNA that occur in different processes and can accumulate over time. DNA damage is a major component of photoaging. In the present study, we are interested in the damage created by UVB in melanocytes.
Les dimères de pyrimidine résultent d’un effet direct des UVB sur les bases pyrimidiques de l’ADN. Il y a formation de dimères cyclobutaniques de pyrimidine (ou CPD pour Cyclobutane Pyrimidine Dimer) qui sont les dommages de l’ADN les plus fréquemment induits par les UVB. Dans les mélanocytes, les CPDs continuent à être générés plus de 3 heures après l’exposition aux UVB. Ils sont appelés « dark CPDs » et sont dus à la chemiexcitation de la mélanine, conduisant à un transfert d’énergie à l’ADN. Pyrimidine dimers result from a direct effect of UVB on pyrimidine bases in DNA. There is formation of cyclobutane pyrimidine dimers (or CPD for Cyclobutane Pyrimidine Dimer) which is the most common DNA damage induced by UVB. In melanocytes, CPDs continue to be generated more than 3 hours after exposure to UVB. They are called "dark CPDs" and are caused by the chemexcitation of melanin, leading to energy transfer to DNA.
Dans cette étude, la capacité de l’extrait de l’exemple 1 à réduire la formation des « dark CPDs » dans les mélanocytes a été évaluée. In this study, the ability of the extract from Example 1 to reduce the formation of "dark CPDs" in melanocytes was assessed.
[148] Protocole : [148] Protocol:
Des mélanocytes extraits de l’épiderme humain sont traités par l’extrait de l’exemple 1 à 0,1 % (dilution volume/volume) pendant la nuit, puis irradiés par des UVB à 60 mJ/cm2 et de nouveau traités une nuit par l’extrait de lavande. Le
lendemain matin, les dimères de pyrimidines sont détectés par immunomarquage avec un anticorps dirigé contre les CPDs (Cyclobutane Pyrimidine Dimers Mouse Monoclonal, Euromedex). Après une heure et demie d’incubation suivie de rinçages, les cellules sont incubées en présence de l’anticorps secondaire anti souris couplé à un fluorophore (Alexa Fluor® 488, Invitrogen). Les cellules sont ensuite examinées au microscope à Epi-fluorescence (Zeiss Axiovert 200M microscope). La présence des CPDs est alors observée et quantifiée par analyse d’image (Volocity® image analysis software, Improvision). Melanocytes extracted from the human epidermis are treated with the extract of Example 1 at 0.1% (volume / volume dilution) overnight, then irradiated with UVB at 60 mJ / cm2 and again treated overnight. by lavender extract. the the next morning, the pyrimidine dimers are detected by immunostaining with an antibody directed against the CPDs (Cyclobutane Pyrimidine Dimers Mouse Monoclonal, Euromedex). After an hour and a half of incubation followed by rinsing, the cells are incubated in the presence of the secondary anti-mouse antibody coupled to a fluorophore (Alexa Fluor® 488, Invitrogen). The cells are then examined under an Epi-fluorescence microscope (Zeiss Axiovert 200M microscope). The presence of the CPDs is then observed and quantified by image analysis (Volocity® image analysis software, Improvision).
[149] Résultats : [149] Results:
Dans les conditions non irradiées, les mélanocytes ne présentent pas de CPDs. Leur formation est induite à la suite du stress UVB. L’application de l’extrait de l’exemple 1 sur les mélanocytes a permis de réduire l’induction des « dark CPDs » par les UVB de -37 % (hautement significatif d’après le test t de Student par rapport aux cellules irradiées non traitées). Dans les mêmes conditions et à la concentration égale de 0,1 %, le macérat de lavande obtenu selon l’exemple 2 n’a pas eu d’effet significatif. Under non-irradiated conditions, the melanocytes do not exhibit CPDs. Their formation is induced as a result of UVB stress. The application of the extract of Example 1 on the melanocytes made it possible to reduce the induction of "dark CPDs" by UVB by -37% (highly significant according to Student's t test compared to irradiated cells. untreated). Under the same conditions and at an equal concentration of 0.1%, the lavender macerate obtained according to Example 2 did not have a significant effect.
[150] Conclusion : [150] Conclusion:
L’extrait de l’exemple 1 a diminué les « dark CPDs » produits dans les mélanocytes par un stress UVB. Par cette activité, l’extrait de lavande a montré un bénéfice sur la réduction des dommages de l’ADN, contribuant aux mécanismes de réparation de la peau pendant la nuit. The extract from Example 1 decreased "dark CPDs" produced in melanocytes by UVB stress. Through this activity, lavender extract has been shown to benefit in reducing DNA damage, contributing to the skin's repair mechanisms overnight.
[151] Exemple 5 : Evaluation de l’extrait de l’exemple 1 sur la voie de synthèse de la mélatonine dans des biopsies de peau ex vivo et des follicules pileux humains : [151] Example 5: Evaluation of the extract of Example 1 on the melatonin synthesis pathway in ex vivo skin biopsies and human hair follicles:
[152] Principe : [152] Principle:
Le but de cette expérience est de démontrer un effet de l’extrait de de l’exemple 1 sur la synthèse de mélatonine dans des biopsies de peau humaine en culture. Cette évaluation inclut deux marqueurs : 1 - l’enzyme AANAT (Aralkylamine N- Acetyltransferase ou sérotonine N-acétyl transférase ou timezyme) qui catalyse la N-acétylation de la sérotonine en N-acetylserotonine, ultime étape de la synthèse de la mélatonine, 2 - l’évaluation de la mélatonine elle-même. L’enzyme AANAT contrôle le rythme jour/nuit de production de la mélatonine au niveau de
la glande pinéale. La mélatonine étant aussi synthétisée localement au niveau de la peau, nous avons voulu suivre sa synthèse en réponse à l’application de l’extrait de lavande. The aim of this experiment is to demonstrate an effect of the extract of Example 1 on the synthesis of melatonin in biopsies of human skin in culture. This evaluation includes two markers: 1 - the enzyme AANAT (Aralkylamine N-Acetyltransferase or serotonin N-acetyl transferase or timezyme) which catalyzes the N-acetylation of serotonin to N-acetylserotonin, the final step in the synthesis of melatonin, 2 - the evaluation of melatonin itself. The AANAT enzyme controls the day / night rate of melatonin production at the level of the pineal gland. As melatonin is also synthesized locally in the skin, we wanted to follow its synthesis in response to the application of lavender extract.
[153] Protocole : [153] Protocol:
L’enzyme AANAT et la mélatonine sont évaluées par immunofluorescence indirecte sur des biopsies de peau, traitées au préalable par application topique de l’extrait de lavande pendant 48 heures (2 fois par jour). De plus, l’extrait de l’exemple 1 dilué à 0,5 % (dilution volume/volume) dans le milieu de culture a été mis au contact de follicules pileux humains, isolés à partir de biopsies de cuir chevelu. Des biopsies contrôles incubées en parallèle dans les mêmes conditions, ainsi que des follicules pileux contrôles sans addition de l’extrait de lavande, reçoivent le placebo (Phosphate Buffer Saline, PBS). Au terme de l’incubation, les biopsies et les follicules pileux sont fixés et inclus en paraffine pour la réalisation de coupes histologiques. La détection de l’enzyme AANAT et de la mélatonine est réalisée par incubation avec les anticorps respectifs : anti- AANAT (Invitrogen) et anti-mélatonine (Abnova, Cliniscience). Après une heure et demie d’incubation suivie de rinçages, les coupes sont incubées en présence de l’anticorps secondaire anti-lapin couplé à un fluorophore (Alexa Fluor® 488, Invitrogen). Les coupes sont ensuite examinées au microscope à Epi- fluorescence (Zeiss Axiovert 200M microscope). L’expression de collagène I est alors observée et quantifiée par analyse d’image (Volocity® image analysis software, Improvision). The AANAT enzyme and melatonin are evaluated by indirect immunofluorescence on skin biopsies, previously treated with topical application of lavender extract for 48 hours (twice a day). In addition, the extract of Example 1 diluted to 0.5% (volume / volume dilution) in the culture medium was contacted with human hair follicles, isolated from scalp biopsies. Control biopsies incubated in parallel under the same conditions, as well as control hair follicles without addition of lavender extract, receive the placebo (Phosphate Buffer Saline, PBS). At the end of the incubation, the biopsies and the hair follicles are fixed and embedded in paraffin for the realization of histological sections. The detection of the enzyme AANAT and of melatonin is carried out by incubation with the respective antibodies: anti-AANAT (Invitrogen) and anti-melatonin (Abnova, Cliniscience). After an hour and a half of incubation followed by rinses, the sections are incubated in the presence of the secondary anti-rabbit antibody coupled to a fluorophore (Alexa Fluor® 488, Invitrogen). The sections are then examined under an Epifluorescence microscope (Zeiss Axiovert 200M microscope). The expression of collagen I is then observed and quantified by image analysis (Volocity® image analysis software, Improvision).
[154] Résultat : [154] Result:
L’évaluation de l’enzyme AANAT et de la mélatonine a montré une augmentation de +20 % et de +51 %, respectivement dans les biopsies de peau traitées avec l’extrait de l’exemple 1 à 0,5% (hautement significatif d’après le test t de Student, comparé aux biopsies recevant le placebo). Le macérat de lavande obtenu selon l’exemple 2 a donné un résultat équivalent en ce qui concerne l’AANAT, mais a conduit à une plus faible augmentation pour la mélatonine (+34 %, hautement significatif d’après le test t de Student, comparé aux biopsies recevant le placebo). Dans les follicules pileux en culture, l’extrait de l’exemple 1 à 0,5 % a
entraîné une augmentation de la production de mélatonine de l’ordre de +23 %, observée dans la gaine épithéliale externe des follicules. Evaluation of the AANAT enzyme and melatonin showed an increase of + 20% and + 51%, respectively in skin biopsies treated with the extract of Example 1 at 0.5% (highly significant according to Student's t test, compared to biopsies receiving placebo). The lavender macerate obtained according to Example 2 gave an equivalent result with regard to AANAT, but led to a smaller increase for melatonin (+ 34%, highly significant according to Student's t test, compared to biopsies receiving placebo). In the hair follicles in culture, the extract of Example 1 at 0.5% has resulted in an increase in melatonin production of the order of + 23%, observed in the outer epithelial sheath of the follicles.
[155] Conclusion : [155] Conclusion:
L’extrait de l’exemple 1 a montré une activité sur la production de la mélatonine dans les biopsies de peau ex vivo et dans les follicules pileux. Cette augmentation est liée à une augmentation de l’enzyme AANAT, dont l’expression est augmentée dans la glande pinéale au cours de la transition du jour à la nuit. Les propriétés de la mélatonine sont liées à des activités de réparation des dommages cellulaires, notamment au niveau de l’ADN et en raison de son activité antioxydante. L’augmentation de la mélatonine dans la peau par l’extrait de lavande apparaît donc bénéfique pour les processus de réparation des dommages de la peau pendant la nuit. L’augmentation de la mélatonine dans le follicule pileux indique un effet bénéfique sur la physiologie du follicule pileux, la mélatonine étant associée à la phase de croissance du cheveu. The extract from Example 1 showed activity on melatonin production in ex vivo skin biopsies and in hair follicles. This increase is related to an increase in the enzyme AANAT, which is increased in expression in the pineal gland during the transition from day to night. The properties of melatonin are linked to cell damage repair activities, especially at the DNA level and due to its antioxidant activity. The increase in melatonin in the skin by lavender extract therefore appears to be beneficial for the damage repair processes of the skin overnight. The increase in melatonin in the hair follicle indicates a beneficial effect on the physiology of the hair follicle, since melatonin is associated with the growth phase of the hair.
[156] Exemple 6 : Evaluation du potentiel éclaircissant de l’extrait de l’exemple 1 sur des biopsies de peau ex vivo : [156] Example 6: Evaluation of the lightening potential of the extract of Example 1 on ex vivo skin biopsies:
[157] Principe : [157] Principle:
Le but de cette étude est d’évaluer le potentiel éclaircissant de l’extrait de l’exemple 1 sur des biopsies de peau ex vivo, en utilisant la coloration histologique de la mélanine Fontana-Masson, basée sur la réduction d’une solution de nitrate d'argent ammoniacal en argent métallique. La coloration obtenue révèle le contenu en mélanine et est quantifiée par analyse d’images. The aim of this study is to evaluate the lightening potential of the extract of Example 1 on ex vivo skin biopsies, using the histological staining of Fontana-Masson melanin, based on the reduction of a solution of ammoniacal silver nitrate in metallic silver. The color obtained reveals the melanin content and is quantified by image analysis.
[158] Protocole : [158] Protocol:
Des biopsies de peau humaine ex vivo sont mises en culture et traitées par l’extrait de l’exemple 1 à 0,5 % (dilution volume/volume) et 1 % (dilution volume/volume) pendant 48 heures. Après traitement, les biopsies sont fixées pour analyse histologique et incluses en paraffine. Après déparaffinage, les coupes sont incubées avec la solution de nitrate d’argent ammoniacal, à 60°C pendant 10 minutes. Après rinçage, elles sont traitées par le Sodium Thiosulfate 5 % pendant 2 minutes, puis rincées à nouveau et montées pour l’examen au microscope Eclipse E600 (Nikon). Les photos sont prises avec la caméra
Qlmaging Retiga 2000R Fast1394 et analysées par le logiciel Q-Capture Pro 7 (Qlmaging). Ex vivo human skin biopsies are cultured and treated with the extract of Example 1 at 0.5% (volume / volume dilution) and 1% (volume / volume dilution) for 48 hours. After treatment, the biopsies are fixed for histological analysis and embedded in paraffin. After dewaxing, the sections are incubated with the ammoniacal silver nitrate solution at 60 ° C. for 10 minutes. After rinsing, they are treated with 5% sodium thiosulphate for 2 minutes, then rinsed again and mounted for examination under an Eclipse E600 microscope (Nikon). Photos are taken with the camera Qlmaging Retiga 2000R Fast1394 and analyzed by Q-Capture Pro 7 software (Qlmaging).
[159] Résultats et conclusion : [159] Results and conclusion:
Sur des biopsies de peau ex vivo, une diminution du contenu en mélanine de moins 55 % et de moins 72 %, a été observée après application de l’extrait de l’exemple 1 à 0,5 % (dilution volume/volume) et 1 % (dilution volume/volume) respectivement (hautement significatif par le test t de Student par rapport aux biopsies placebos), tandis que le macérat de lavande obtenu selon l’exemple 2 n’a pas montré de diminution à 0,5 %, et une diminution plus faible (de -47 %) à 1 %. On ex vivo skin biopsies, a decrease in melanin content of minus 55% and minus 72% was observed after application of the extract of Example 1 at 0.5% (volume / volume dilution) and 1% (volume / volume dilution) respectively (highly significant by Student's t test compared to placebos biopsies), while the lavender macerate obtained according to Example 2 did not show a decrease to 0.5%, and a smaller decrease (from -47%) to 1%.
[160] Ce test a donc permis de conclure à un potentiel effet éclaircissant de l’extrait de l’exemple 1 de Lavandula angustifolia sur les biopsies de peau ex vivo. [160] This test therefore made it possible to conclude that there is a potential lightening effect of the extract of Example 1 of Lavandula angustifolia on ex vivo skin biopsies.
[161] Exemple 7 : Formule d’une crème riche [161] Example 7: Formula of a rich cream
[162] [Tableau 5] [162] [Table 5]
Ingrédients (Nom de marque) INCI % w/w
Ingredients (Brand name) INCI% w / w
[163] Procédé de préparation : [163] Preparation process:
1. Homogénéiser la phase A dans le récipient principal et commencer à chauffer à 75-80°C ; 1. Homogenize phase A in the main vessel and start heating to 75-80 ° C;
2. A 30°C, saupoudrer dans la Phase B et homogénéiser tout en chauffant ;2. At 30 ° C, sprinkle in Phase B and homogenize while heating;
3. Dans un bêcher à part, préparer la phase C, chauffer à 75-80°C jusqu'à homogénéité ; 3. In a separate beaker, prepare phase C, heat to 75-80 ° C until homogeneous;
4. A 75°C, ajouter la phase C dans le récipient principal et homogénéiser pendant 10 minutes ; 4. At 75 ° C, add phase C to the main vessel and homogenize for 10 minutes;
5. Laisser refroidir la température et ajouter la phase D à 65°C. Bien mélanger pour homogénéiser pendant 10 minutes ; 5. Allow the temperature to cool and add phase D to 65 ° C. Mix well to homogenize for 10 minutes;
6. Prémélanger la phase E avant de l'ajouter dans le récipient principal ; 6. Premix phase E before adding it to the main container;
7. Ajouter la phase E à 60°C. Bien mélanger pour homogénéiser pendant 10 minutes ; 7. Add phase E at 60 ° C. Mix well to homogenize for 10 minutes;
8. A 35°C, prémélanger la phase F avant de l'ajouter et de bien mélanger ;8. At 35 ° C, premix phase F before adding it and mixing well;
9. Prémélanger la phase G avant de l'ajouter dans le récipient principal ; 9. Premix phase G before adding it to the main container;
10. Ajouter la phase G à 35°C. Bien mélanger pour homogénéiser ; 10. Add phase G at 35 ° C. Mix well to homogenize;
11. Dans un bêcher à part, préparer la phase H : saupoudrer Natrosol™ dans
l'eau à température ambiante et homogénéiser tout en chauffant à 60°C ; 11. In a separate beaker, prepare phase H: sprinkle Natrosol ™ in water at room temperature and homogenize while heating to 60 ° C;
12. Ajouter la phase H à 30°C. Bien mélanger pour homogénéiser ; 12. Add phase H at 30 ° C. Mix well to homogenize;
13. Arrêter à 25°C. 13. Stop at 25 ° C.
[164] La composition se présente ainsi sous forme d’une crème beurre rose, avec un pH compris entre 4,90 et 5,40 et une viscosité (DO) de 160000 - 210000 cps (Brookfield RVT/Spindle D/5 RPM/1 minute/25°C). [164] The composition is thus in the form of a pink buttercream, with a pH between 4.90 and 5.40 and a viscosity (OD) of 160,000 - 210,000 cps (Brookfield RVT / Spindle D / 5 RPM / 1 minute / 25 ° C).
[165] Exemple 8 : Formule d’un masque anti-âge [165] Example 8: Formula of an anti-aging mask
[166] [Tableau 6] [166] [Table 6]
Ingrédients (Nom de marque) INCI % w/w
[167] Procédé de préparation : Ingredients (Brand name) INCI% w / w [167] Preparation process:
1. A 25°C, homogénéiser la phase A dans le récipient principal ; 1. At 25 ° C, homogenize phase A in the main vessel;
2. A 25°C, saupoudrer dans la phase B et bien mélanger jusqu'à homogénéité ;2. At 25 ° C, sprinkle in phase B and mix well until homogeneous;
3. A 25°C, ajouter la phase C et bien mélanger jusqu'à homogénéité ; 3. At 25 ° C, add phase C and mix well until homogeneous;
4. Prémélanger la phase D dans un bêcher à part et ajouter dans le récipient principal à 25°C ; 4. Premix phase D in a separate beaker and add to the main vessel at 25 ° C;
5. A 25°C, ajouter la phase E dans le récipient principal et bien mélanger ;5. At 25 ° C, add phase E to the main container and mix well;
6. Prémélanger la phase F et l'ajouter lentement. Bien mélanger jusqu'à homogénéité ; 6. Premix phase F and add slowly. Mix well until blended;
7. Prémélanger la phase G dans un bêcher à part et ajouter dans le récipient principal jusqu'à homogénéité ; 7. Premix phase G in a separate beaker and add to the main container until blended;
8. Arrêter à 25°C. 8. Stop at 25 ° C.
[168] La composition se présente ainsi sous forme d’un gel crème avec des effets vert scintillant, avec un pH compris entre 5,30 et 5,80 et une viscosité (DO) de 70000 - 100000 cps (Brookfield RVT/Spindle C/5 RPM/1 minute/25°C). [168] The composition is thus in the form of a cream gel with scintillating green effects, with a pH between 5.30 and 5.80 and a viscosity (OD) of 70,000 - 100,000 cps (Brookfield RVT / Spindle C / 5 RPM / 1 minute / 25 ° C).
[169] Exemple 9 : Formule d’un Sérum [169] Example 9: Formula of a Serum
[170] [Tableau 7] [170] [Table 7]
Ingrédients (Nom de marque) INCI % w/w
Ingredients (Brand name) INCI% w / w
[171] Procédé de préparation : [171] Preparation process:
1. Ajouter de l'eau dans le récipient principal et commencer le mélange avec une pale d'hélice hi-lo ; 1. Add water to the main container and start mixing with a hi-lo propeller blade;
2. Ajouter le reste des ingrédients, l’un après l’autre tout en mélangeant entre chaque addition. 2. Add the remaining ingredients, one at a time, stirring between each addition.
[172] La composition se présente ainsi sous forme d’un sérum lisse, semi-opaque, avec un pH compris entre 5,75 et 6,25 et une viscosité (DO) de 1 , 100 - 1 ,400 cps (Brookfield RVT/spindle 3/20 rpm/25°C/1 minute).
[172] The composition is thus in the form of a smooth, semi-opaque serum, with a pH between 5.75 and 6.25 and a viscosity (OD) of 1.100 - 1.400 cps (Brookfield RVT / spindle 3/20 rpm / 25 ° C / 1 minute).
Claims
[Revendication 1] Procédé d’obtention d’un extrait aqueux de parties aériennes de lavande, comprenant les étapes suivantes : a) on met en présence les parties aériennes de lavande avec de l’eau ; b) on ajoute de l’acide phytique à une concentration comprise entre 1 et 10 mM dans le mélange obtenu en a) à un pH compris entre 10 et 11 ; c) on ajuste ensuite le pH du mélange obtenu en b) à une valeur comprise entre 6 et 8 ; d) on purifie le mélange obtenu en c) de manière à éliminer la matière végétale solide résiduelle et obtenir un extrait brut aqueux purifié ; et e) on contrôle le pH et on le réajuste si nécessaire à une valeur comprise entre 6 et 8, préférentiellement entre 6 et 6,5. [Claim 1] A process for obtaining an aqueous extract of aerial parts of lavender, comprising the following steps: a) the aerial parts of lavender are brought into contact with water; b) phytic acid is added at a concentration of between 1 and 10 mM in the mixture obtained in a) at a pH of between 10 and 11; c) the pH of the mixture obtained in b) is then adjusted to a value between 6 and 8; d) the mixture obtained in c) is purified so as to eliminate the residual solid plant material and to obtain a purified aqueous crude extract; and e) the pH is checked and it is readjusted if necessary to a value between 6 and 8, preferably between 6 and 6.5.
[Revendication 2] Procédé selon la revendication 1 caractérisé en ce que dans l’étape a) on met en présence les parties aériennes de lavande, préalablement séchées puis broyées, avec de l’eau dans un rapport matière végétale / eau compris entre 3 et 20 % (poids/poids). [Claim 2] The method of claim 1 characterized in that in step a) the aerial parts of lavender, previously dried and then ground, are brought together with water in a plant material / water ratio of between 3 and 20% (w / w).
[Revendication 3] Procédé selon l’une des revendications 1 ou 2 caractérisé en ce que l’étape b) de traitement par l’acide phytique à une concentration de 3 mM et est réalisé sous agitation pendant un temps d’au moins 1h et à une température comprise entre 20 et 80°C. [Claim 3] Method according to one of claims 1 or 2 characterized in that step b) of treatment with phytic acid at a concentration of 3 mM and is carried out with stirring for a time of at least 1 hour and at a temperature between 20 and 80 ° C.
[Revendication 4] Procédé selon l’une des revendications 1 à 3 caractérisé en ce que l’étape e) est précédée par au moins une filtration de l’extrait brut aqueux obtenu en d) et préférentiellement par des filtrations successives de l’extrait brut aqueux en abaissant le seuil de filtration de 20-50 pm à 0,10-0,30 pm. [Claim 4] Method according to one of claims 1 to 3, characterized in that step e) is preceded by at least one filtration of the crude aqueous extract obtained in d) and preferably by successive filtrations of the extract. crude aqueous by lowering the filtration threshold from 20-50 µm to 0.10-0.30 µm.
[Revendication 5] Procédé selon l’une des revendications 1 à 4 caractérisé en ce que les parties aériennes de lavande sont de l’espèce Lavandula angustifolia. [Claim 5] A method according to one of claims 1 to 4 characterized in that the aerial parts of lavender are of the species Lavandula angustifolia.
[Revendication 6] Extrait aqueux de parties aériennes de lavande enrichi en petits ARN d’une longueur d’au maximum 150 nucléotides, en sucres, en composés phénoliques et en acides organiques, dépourvu d’ADN, susceptible
d’être obtenu par le procédé de l’une des revendications 1 à 5, caractérisé en ce qu’il comprend en poids du poids total de l’extrait, 10 à 30 g/kg de poids sec, contenant 2 à 10 g/kg de sucres, 100 à 1500 mg/kg d’acides organiques, 500 à 2000 mg/kg de composés phénoliques et 40 à 200 mg/kg d’ARN de petits poids moléculaires d’une longueur d’au maximum 150 nucléotides.[Claim 6] Aqueous extract of aerial parts of lavender enriched with small RNAs of up to 150 nucleotides in length, sugars, phenolics and organic acids, devoid of DNA, susceptible to be obtained by the process of one of claims 1 to 5, characterized in that it comprises, by weight of the total weight of the extract, 10 to 30 g / kg of dry weight, containing 2 to 10 g / kg of sugars, 100 to 1500 mg / kg of organic acids, 500 to 2000 mg / kg of phenolic compounds and 40 to 200 mg / kg of RNA of small molecular weights of up to 150 nucleotides in length.
[Revendication 7] Extrait selon la revendication 6, caractérisé en ce qu’il est ultérieurement dilué dans un solvant et comprend en poids du poids total de l’extrait, 4 à 20 g/kg d’extrait sec, 0,5 à 10 g/kg de sucres, 50 à 700 mg/kg d’acides organiques, 50 à 1500 mg/kg de composés phénoliques et 10 à 100 mg/kg d’ARN de petits poids moléculaires d’une longueur d’au maximum 150 nucléotides. [Claim 7] Extract according to claim 6, characterized in that it is subsequently diluted in a solvent and comprises by weight of the total weight of the extract, 4 to 20 g / kg of dry extract, 0.5 to 10 g / kg of sugars, 50 to 700 mg / kg of organic acids, 50 to 1500 mg / kg of phenolic compounds and 10 to 100 mg / kg of low molecular weight RNA with a maximum length of 150 nucleotides .
[Revendication 8] Composition comprenant, en tant qu’ingrédient actif, une quantité efficace de l’extrait de l’une des revendications 6 ou 7, et un milieu physiologiquement acceptable. [Claim 8] A composition comprising, as an active ingredient, an effective amount of the extract of one of claims 6 or 7, and a physiologically acceptable medium.
[Revendication 9] Composition selon la revendication 8, caractérisée en ce que l’extrait est présent à une concentration comprise entre 0,05 et 5 % en poids du poids total de la composition et préférentiellement entre 0,1 à 1 ,0 % en poids du poids total de la composition. [Claim 9] Composition according to Claim 8, characterized in that the extract is present at a concentration of between 0.05 and 5% by weight of the total weight of the composition and preferably between 0.1 to 1.0% by weight. weight of the total weight of the composition.
[Revendication 10] Composition selon l’une des revendications 8 ou 9, caractérisée en ce qu’elle est formulée pour être appliquée topiquement sur la peau, les phanères et le cuir chevelu. [Claim 10] Composition according to one of claims 8 or 9, characterized in that it is formulated to be applied topically to the skin, integuments and the scalp.
[Revendication 11] Utilisation cosmétique de la composition de l’une des revendications 8 à 10 pour le soin de la peau, du cuir chevelu et des phanères et plus particulièrement pour protéger la peau des agressions externes et de l’oxydation, lutter contre les signes du vieillissement cutané, augmenter la photoprotection, éclaircir la peau, améliorer l’hydratation de la peau, renforcer la fonction barrière ou encore apaiser la peau. [Claim 11] Cosmetic use of the composition of one of claims 8 to 10 for caring for the skin, scalp and integuments and more particularly for protecting the skin from external attacks and oxidation, to fight against signs of skin aging, increase photoprotection, lighten the skin, improve skin hydration, strengthen the barrier function or even soothe the skin.
[Revendication 12] Utilisation cosmétique de la composition de l’une des revendications 8 à 10 pour améliorer les mécanismes biologiques associés à la réparation de la peau pendant la nuit.
[Claim 12] Cosmetic use of the composition of any of claims 8 to 10 for improving biological mechanisms associated with overnight skin repair.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2001107A FR3106754B1 (en) | 2020-02-04 | 2020-02-04 | METHOD FOR OBTAINING AN AQUEOUS LAVENDER EXTRACT, COMPOSITIONS COMPRISING SUCH AN EXTRACT AND THEIR COSMETIC USES |
PCT/EP2021/051734 WO2021156104A1 (en) | 2020-02-04 | 2021-01-26 | Method for obtaining an aqueous extract of lavender, compositions comprising such an extract and their cosmetic uses |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4099975A1 true EP4099975A1 (en) | 2022-12-14 |
Family
ID=70154741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21702221.9A Pending EP4099975A1 (en) | 2020-02-04 | 2021-01-26 | Method for obtaining an aqueous extract of lavender, compositions comprising such an extract and their cosmetic uses |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230390182A1 (en) |
EP (1) | EP4099975A1 (en) |
JP (1) | JP2023513504A (en) |
KR (1) | KR20220137036A (en) |
CN (1) | CN115135301B (en) |
AU (1) | AU2021217737A1 (en) |
BR (1) | BR112022014462A2 (en) |
CA (1) | CA3164351A1 (en) |
FR (1) | FR3106754B1 (en) |
WO (1) | WO2021156104A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3116438B1 (en) * | 2020-11-23 | 2022-10-14 | Isp Investments Llc | METHOD FOR OBTAINING AQUEOUS EXTRACTS FROM TEA LEAVES, COMPOSITIONS COMPRISING SUCH EXTRACTS AND THEIR COSMETIC USES |
CN114159985B (en) * | 2021-12-30 | 2022-09-27 | 江苏久膜高科技股份有限公司 | Composite membrane for purifying lavender essential oil and preparation method thereof |
FR3132436A1 (en) * | 2022-02-08 | 2023-08-11 | Isp Investments Llc | METHOD FOR OBTAINING PLANT EXTRACTS COMPRISING A SELF-FERMENTATION STEP, COMPOSITIONS COMPRISING SUCH EXTRACTS AND THEIR COSMETIC USES |
FR3133755A1 (en) * | 2022-03-24 | 2023-09-29 | International Flavors & Fragrances Inc. | Cosmetic use of lavandin extract as a protective or anti-fatigue cosmetic agent |
FR3134515A1 (en) * | 2022-04-14 | 2023-10-20 | Isp Investments Llc | Crocus sativus flower extracts, compositions comprising them and their uses in oral care |
WO2024006751A1 (en) | 2022-06-29 | 2024-01-04 | Isp Investments Llc | Method of cosmetic treatment for improving the skin night-time renewal process and for protecting the skin from free radicals associated with blue light exposure |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1540597C3 (en) | 1965-11-29 | 1975-01-16 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | High voltage bushing |
JPH11199469A (en) | 1998-01-12 | 1999-07-27 | Shiseido Co Ltd | Cosmetic and cleansing agent |
FR2817748B1 (en) | 2000-12-13 | 2003-01-17 | Seporga | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING ARTEMIA SALINA EXTRACT |
FR2827170B1 (en) | 2001-07-13 | 2004-07-16 | Soc Extraction Principes Actif | USE OF PEPTIDES TO INCREASE CELL ADHESION |
FR2831168B1 (en) | 2001-10-22 | 2004-02-06 | Rocher Yves Biolog Vegetale | PROCESS FOR OBTAINING A NUCLEIC ACID-RICH EXTRACT FROM PLANT MATERIAL |
FR2837098B1 (en) | 2002-03-18 | 2004-05-28 | Vincience | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING PEPTIDES, METHODS OF TREATMENT AND USES |
CA2485111A1 (en) | 2002-06-03 | 2003-12-11 | L'oreal | Topical use of at least one double-stranded rna oligonucleotide (ds rna) |
FR2841781B1 (en) | 2002-07-03 | 2005-12-16 | USE OF PEPTIDES TO PROMOTE SKIN REGENERATION | |
FR2846883B1 (en) | 2002-11-08 | 2004-12-24 | Vincience | COSMETIC COMPOSITION COMPRISING, AS ACTIVE INGREDIENT, AT LEAST ONE PEPTIDE AND USE OF THIS PEPTIDE |
FR2885808B1 (en) | 2005-05-19 | 2007-07-06 | Oreal | VECTORIZATION OF DSRNA BY CATIONIC PARTICLES AND TOPICAL USE. |
CN101518506B (en) * | 2009-03-26 | 2010-09-29 | 上海交通大学 | Aromatic plant extract for anti-allergic skin care product |
FR2951946B1 (en) | 2009-11-03 | 2012-05-11 | Isp Investments Inc | USE OF PEPTIDE HYDROLYSAT OF YEAST AS AN ACTIVE AGENT FOR STRENGTHENING THE HAIR |
FR2944526B1 (en) | 2009-04-15 | 2013-05-10 | Isp Investments Inc | COSMETIC AND / OR PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE HYDROLYZATE CAPABLE OF STRENGTHENING BARRIER FUNCTION |
FR2956818B1 (en) | 2010-02-26 | 2012-07-20 | Isp Investments Inc | USE OF PEPTIDE LINK HYDROLYSAT IN A COMPOSITION FOR SOOTHING SKIN |
CN103385830A (en) | 2013-07-19 | 2013-11-13 | 石强 | Traditional Chinese medicine composition and its preparation method and use |
KR20150042999A (en) | 2013-10-14 | 2015-04-22 | 을지대학교 산학협력단 | Composition of Skin Soothining Cosmetics for Acne Skin Using Eco-friendly Supercritical Lavender Extract |
FR3043695B1 (en) | 2015-11-17 | 2019-10-25 | ISP Investments LLC. | PROCESS FOR OBTAINING AQUEOUS EXTRACT ENRICHED IN SMALL RNA FROM PLANT MATERIAL AND EXTRACTS FROM THE PROCESS |
FR3066113B1 (en) * | 2017-05-12 | 2020-06-05 | ISP Investments LLC. | PROCESS FOR OBTAINING AN AQUEOUS EXTRACT OF GRAVEOLENS ANETHUM ENRICHED IN SMALL RNA |
CN107669865A (en) * | 2017-11-08 | 2018-02-09 | 广西南宁胜祺安科技开发有限公司 | A kind of anti-senile dementia disease oral agents |
-
2020
- 2020-02-04 FR FR2001107A patent/FR3106754B1/en active Active
-
2021
- 2021-01-26 BR BR112022014462A patent/BR112022014462A2/en unknown
- 2021-01-26 CN CN202180013219.3A patent/CN115135301B/en active Active
- 2021-01-26 CA CA3164351A patent/CA3164351A1/en active Pending
- 2021-01-26 JP JP2022547288A patent/JP2023513504A/en active Pending
- 2021-01-26 KR KR1020227029072A patent/KR20220137036A/en unknown
- 2021-01-26 US US17/795,389 patent/US20230390182A1/en active Pending
- 2021-01-26 EP EP21702221.9A patent/EP4099975A1/en active Pending
- 2021-01-26 AU AU2021217737A patent/AU2021217737A1/en active Pending
- 2021-01-26 WO PCT/EP2021/051734 patent/WO2021156104A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN115135301B (en) | 2024-08-16 |
BR112022014462A2 (en) | 2022-09-13 |
JP2023513504A (en) | 2023-03-31 |
CN115135301A (en) | 2022-09-30 |
KR20220137036A (en) | 2022-10-11 |
WO2021156104A1 (en) | 2021-08-12 |
AU2021217737A1 (en) | 2022-09-01 |
US20230390182A1 (en) | 2023-12-07 |
FR3106754A1 (en) | 2021-08-06 |
CA3164351A1 (en) | 2021-08-12 |
FR3106754B1 (en) | 2022-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021156104A1 (en) | Method for obtaining an aqueous extract of lavender, compositions comprising such an extract and their cosmetic uses | |
EP3377623B1 (en) | Process for obtaining an aqueous extract enriched with small rnas from a plant material and extracts resulting from the process | |
JP5937965B2 (en) | Full seed extract of Moringa species and its use in cosmetic and / or dermatological compositions | |
FR3065172A1 (en) | COSMETIC PREPARATION CONTAINING WHITE TRUFFLE EXTRACT AND ASSOCIATED COSMETIC PROCESS | |
CA2258800A1 (en) | Antioxidant and/or antielastase composition based on lupine oil | |
EP3280497B1 (en) | Hydroalcoholic extract ofschinus molle, cosmetic compositions comprising the same and cosmetic uses thereof | |
FR3110417A1 (en) | Absolute for their cosmetic use | |
EP3269426B1 (en) | Extract of aesculus hippocastanum | |
EP3980123B1 (en) | Moringa peregrina seed extract rich in 2,5-diformylfuran, process for obtaining same and use thereof in cosmetic compositions | |
FR3066114B1 (en) | COMPOSITION COMPRISING AN AQUEOUS EXTRACT OF ANETHUM GRAVEOLENS ENRICHED IN SMALL RNA AND ITS COSMETIC USES | |
EP3917554B1 (en) | Method for obtaining an extract of patchouli leaves and cosmetic uses thereof | |
EP4262738A1 (en) | Method for obtaining aqueous extracts of tea leaves, compositions comprising such extracts and cosmetic uses thereof | |
WO2023152080A1 (en) | Method for obtaining plant extracts comprising an autofermentation step, compositions comprising such extracts and cosmetic uses thereof | |
WO2023001812A1 (en) | Black tea leaf extract, compositions comprising same and cosmetic uses thereof | |
EP3965728A1 (en) | Agrimony extract as anti-pollution agent | |
FR3110421A1 (en) | Narcissus poeticus extract for its cosmetic use | |
FR3110419A1 (en) | Moringa peregrina seed extract rich in 2,5-diformylfuran, process for obtaining it and its use in cosmetic compositions | |
FR3091994A1 (en) | New cosmetic uses of a rose extract | |
OA21067A (en) | Moringa Peregrina seed extract rich in 2,5-diformylfuran, its process for obtaining it and its use in cosmetic compositions. | |
FR3098119A1 (en) | PROCESS FOR OBTAINING A BOTANICAL THERMAL INFUSION | |
FR3065877A1 (en) | SAP NEEDLE EXTRACTS, COMPOSITIONS AND USES | |
WO2016198756A1 (en) | Cosmetic, nutraceutical, veterinary and pharmaceutical compositions containing a hazelnut pericarp extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220811 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |